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ABSTRACT
Studies of dominantly heritable cancers enabled insights about tumor 
progression. BCNS is a dominantly inherited disorder that is characterized by 
developmental abnormalities and postnatal neoplasms, principally BCCs. We 
performed an exploratory gene expression profiling of primary cell cultures derived 
from clinically unaffected skin biopsies of BCNS gene-carriers (PTCH1 +/-) and 
normal individuals. PCA and HC of untreated keratinocytes or fibroblasts failed to 
clearly distinguish BCNS samples from controls. These results are presumably due 
to the common suppression of canonical HH signaling in vitro. We then used a 
relaxed threshold (p-value <0.05, no FDR cut-off; FC 1.3) that identified a total of 
585 and 857 genes differentially expressed in BCNS keratinocytes and fibroblasts 
samples, respectively. A GSEA identified pancreatic β cell hallmark and mTOR 
signaling genes in BCNS keratinocytes, whereas analyses of BCNS fibroblasts 
identified gene signatures regulating pluripotency of stem cells, including WNT 
pathway. Significantly, rapamycin treatment (FDR<0.05), affected a total of 1411 
and 4959 genes in BCNS keratinocytes and BCNS fibroblasts, respectively. In 
contrast, rapamycin treatment affected a total of 3214 and 4797 genes in normal 
keratinocytes and normal fibroblasts, respectively. The differential response of 
BCNS cells to rapamycin involved 599 and 1463 unique probe sets in keratinocytes 
and fibroblasts, respectively. An IPA of these genes in the presence of rapamycin 
pointed to hepatic fibrosis/stellate cell activation, and HIPPO signaling in BCNS 
keratinocytes, whereas mitochondrial dysfunction and AGRN expression were 
uniquely enriched in BCNS fibroblasts. The gene expression changes seen here are 
likely involved in the etiology of BCCs and they may represent biomarkers/targets 
for early intervention.
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INTRODUCTION
Basal cell carcinomas (BCCs) of the skin represent 
nearly one half of all cancers diagnosed in the United 
States [1, 2]. Although these tumors rarely metastasize and 
are an infrequent cause of cancer mortality [3], they are 
associated with significant morbidity due to local invasion 
and tissue destruction. The basal cell nevus syndrome 
(BCNS), also known as Gorlin syndrome or the nevoid 
basal cell carcinoma syndrome, is an autosomal dominant 
disorder characterized by multiple BCCs, occasional 
childhood malignancies, and developmental defects 
including palmar pits, jaw cysts, coarse facial appearance, 
malformations of the ribs, spine and brain, macrocephaly, 
and generalized overgrowth [4–6].
The majority of BCNS cases can be attributed to 
heterozygous germline mutations in PTCH1; the human 
homolog of the Drosophila gene, patched [7]. Patched 
(PTCH1) encodes the receptor for hedgehog (HH), a 
secreted morphogen involved in establishing the basic 
framework of developing embryos in Drosophila and 
in other organisms, including vertebrates [8, 9]. In the 
canonical pathway, binding of HH to PTCH releases 
inhibition on SMO, which then signals through a series 
of steps to zinc finger trans-activators that ultimately 
convey the signal to the nucleus. In humans, the trans-
activator function is performed by GLI1, GLI2 and GLI3. 
Genes directly regulated by GLI include PTCH1, HIP 
(hedgehog interacting protein), and GLI1 itself, in many 
tissues. A host of other potential target genes in normal 
cells have been identified by expression microarrays 
where it appears that HH signaling is influenced by the 
stage of development and tissue-specific factors [8, 9], 
leading to different global expression patterns in different 
organs [10].
Appropriately, tumor suppressor genes and their 
effector pathways have been identified in several 
dominantly heritable cancers, providing insights about 
cancer initiation and potential intervention [11–13]. 
Analogous to retinoblastoma [11, 12] and other autosomal 
dominant forms of heritable cancer [13–18], BCCs in 
BCNS patients, arise through a two-hit mechanism in 
which “one hit” is an inherited, inactivating mutation 
in PTCH1, and the second hit is a somatically derived 
mutation in the remaining PTCH1 allele [7]. The great 
majority of sporadic BCCs have two somatically derived 
mutations in PTCH1, or less often, an activating mutation 
in SMO that mimics loss of PTCH1 [7, 19–23]. Although 
additional molecular changes are probably necessary for 
the development of BCCs, it is likely that loss of PTCH1 
function and consequent activation of the hedgehog 
pathway is a necessary early step [24, 25].
This “one-hit model” for BCNS is supported by 
many features of this disorder such as developmental 
defects that have a generalized or symmetric manifestation 
which would be difficult to reconcile with a two-hit 
mechanism. Generalized overgrowth, acromegalic bone 
structure, and relative macrocephaly, for example, suggest 
that heterozygous loss of function leads to cellular hyper-
proliferation in bone or cartilage [26]. In this regard, 
expression analysis of BCNS fibroblasts and fibroblasts 
from unaffected individuals [27] implicated genes that 
were hypothesized to contribute to a growth advantage in 
BCNS fibroblasts.
BCNS patients can develop thousands of 
skin tumors over their lifetimes, and treating this 
multiplicity of tumors with conventional surgical or 
other ablative therapies is a challenge. Preventive or 
curative medical therapy with an effective targeted 
agent that is known to have limited adverse, off-target 
effects would represent a great advance. Although 
several compounds are known to inhibit hedgehog 
signaling [28–30], their overall preventative efficacy of 
BCC remains to be established, and side effects limit 
their long-term use. In this regard, it is important to 
note that cell identity switch allows residual BCC to 
survive hedgehog pathway inhibition, necessitating the 
use of an additional agent(s) [31].
Rapamycin, also known as sirolimus, is an 
antibiotic isolated from Streptomyces hygroscopicus 
[32] that blocks mitogenic signaling by growth factor 
receptors and is a promising anti-neoplastic agent for 
a variety of tumors [33–37]. The best studied pathway 
affected by rapamycin is that conducted by the mTOR 
complex 1 (mTORC1), which consists of the mTOR 
protein (a member of the (PI(3)K) family) DEPTOR, 
PRAS40, RAPTOR, mLST8, and TTI1–TEL2 [33–37]. 
Importantly, rapamycin has also been shown to have an 
effect on the canonical HH pathway wherein crosstalk 
between mTOR and HH pathways has been indicated 
[38–40]. Thus, while blocking mTOR may take away a 
signaling component that is necessary but not sufficient 
for transformation, the mTOR and HH pathways 
coincidentally may target an overlapping set of genes 
that are likely to inhibit BCC carcinogenesis. Incidentally, 
rapamycin has been shown to inhibit BCC development 
in kidney transplant patients [41, 42] and has also been 
shown in a case report to inhibit BCCs, advocating its 
use when surgical intervention is counter-indicated [43].
The first aim of this study was to profile 
baseline global gene expression in cells obtained from 
histologically normal skin of BCNS subjects and 
compare these with skin cells from unaffected individuals 
to detect “single-hit” effects caused by PTCH1 (+/-). 
Since hedgehog activation has been proposed to 
function in carcinogenesis through paracrine activity 
on stroma as well as cell autonomous activity [44, 45], 
both keratinocytes and fibroblasts were analyzed in this 
study. Our second aim was to determine if a particular 
set of genes was differentially influenced by rapamycin 
in tissues that might have been “sensitized” to its effect 
by loss of one copy of PTCH1.
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RESULTS
Exploratory analysis at baseline reveals no clear 
association of samples based on PTCH1 mutation 
status
The first goal of this study was to explore changes 
in gene expression that can be attributed to mutations 
in PTCH1 and can possibly contribute to molecular 
abnormalities of basal cell carcinomas. Here we profiled 
gene expression patterns of PTCH1 (+/-) keratinocytes 
and PTCH1 (+/-) fibroblasts derived from histologically 
normal tissues of BCNS subjects and compared them 
to cells derived from normal individuals at baseline 
and following treatment with rapamycin (Table 1). A 
principal components analysis (PCA) (Supplementary 
Figure 1) revealed that although the two treatments 
clustered separately, i.e., with and without rapamycin, the 
differences in gene expression due to PTCH1 mutation 
did not result in a significant clustering and separation 
of BCNS from normal samples, indicating that the 
PTCH1 mutation itself, whether truncating or missense, 
does not alter global gene expression of keratinocytes 
or fibroblasts enough to provide clear separation 
between BCNS and normal specimens. The lack of clear 
delineation of samples at baseline can be attributed to an 
attenuated canonical HH pathway in PTCH1 (+/-) cells 
grown in culture [46, 47]. However, rapamycin treatment 
caused significant changes in global gene expression 
pattern that provided a clear separation of treated and 
untreated samples derived from either BCNS patients or 
normal subjects (Figure 1).
Table 1: Characteristics of cases and controls
Participant ID Gender Age PTCH1 
Sequencing
Mutation 
Type
Clinical features
BCCs Jaw Cysts Pits
Cases
04 F 55 W278X Truncating + + +
11 F 60 W844G1 Missense + + +
12 F 51 W926L2 Missense + + +
14 F 30 Relative of 15, 16 Q853X
3 Truncating + + +
07 M 20 Codon 1124delC Truncating + + +
13 M 25 Relative of 12 W926L2 Missense + + +
17 M 44 C1043X Truncating + + +
18 M 46 IVS15+9 G>C4 Missense + + +
22 M 50 Exon 1E splice acceptor5 Missense + + -
Controls
02 F 41 Not done - - - -
08 F 21 Relative of 07 Wild type - - - -
09 F 27 Not done - - - -
15 F 54 Relative of 14 Wild type - - - -
01 M 37 Not done - - - -
03 M 51 Not done - - - -
05 M 49 Relative of 04 Wild type - - - -
16 M 53 Relative of 14 Wild type - - - -
1Trp at amino acid 844 is 100% conserved in vertebrates and invertebrates. Codon numbering is according to NP_000255.
2Trp at amino acid 926 is 100% conserved in vertebrates and invertebrates; W926R reported previously in BCNS [67].
3Truncating mutation has been reported [67].
4Variant of unknown significance; however, PTCH1 mutations p.W926X/R have been reported in 5 cases [68].
5Creates an abnormal acceptor site predicted to be highly efficient at position 32 of exon 1E (G to A change).
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The PCA results were further supported by 
unsupervised hierarchical clustering of genes (coefficient of 
variation of more than 0.1 in the microarray data) at baseline 
and after rapamycin treatment (Figure 1). While control 
samples distinctly cluster apart from rapamycin treated 
samples for both the keratinocytes (Figure 1A) and fibroblasts 
(Figure 1B), the clustering pattern was independent of PTCH1 
mutation status or rapamycin concentration. Together, these 
results reaffirm our observation that mono-allelic PTCH1 
mutation did not affect the global gene expression pattern to 
distinguish BCNS from normal samples in vitro. Secondly, 
the analysis suggests that the effect of rapamycin at a more 
stringent level of statistical scrutiny (FDR<0.05) is dependent 
on the intrinsic gene expression pattern unique to the sample 
derived from each individual.
Differentially regulated genes in BCNS and 
normal samples at baseline under more relaxed 
statistical constrains
Following 5-way mixed-model ANOVA-REML 
(FC >1.3 and <-1.3; unadjusted p<0.05), we found several 
gene sets that were differentially expressed. Briefly, the 
baseline comparison of microarray data of keratinocytes and 
fibroblasts showed 585 and 857, respectively of differentially 
expressed genes between BCNS and normal subjects. Hence, 
Figure 1: Unsupervised hierarchical clustering of microarray data of keratinocytes (A) and fibroblasts (B) for each subject 
with or without (control) rapamycin treatment. Coefficient of variation of more than 0.1. The subject numbers match the participant 
ID numbers in Table 1. S10 indicates sirolimus/rapamycin low dose and S50 indicates sirolimus/rapamycin high dose.
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Table 2: List of top genes differentially regulated in keratinocytes and fibroblasts derived from BCNS subjects 
compared to normal individuals
Gene Symbol Gene title (HGNC approved) Fold change p-value
Genes up-regulated in BCNS keratinocytes
NFIA-AS2 Nuclear factor I/A antisense RNA 2 1.67846 0.000241
RBMY3AP RNA binding motif protein, Y-linked, family 3, member A pseudogene 1.61282 0.000475
SEC16B SEC16 homolog B (S. cerevisiae) 1.59121 9.05E-05
CROCC ciliary rootlet coiled-coil, rootletin 1.58479 0.000707
SYN1 synapsin I 1.54555 0.000235
MKL1 Megakaryoblastic leukemia (translocation) 1 1.54463 0.004594
FAM71A family with sequence similarity 71, member A 1.53406 0.001157
LOC101928973 uncharacterized 1.53286 0.000580
SIM2 single-minded homolog 2 (Drosophila) 1.52543 0.000744
GNG8 guanine nucleotide binding protein (G protein), gamma 8 1.52347 0.001798
Genes down-regulated in BCNS keratinocytes
GSTT1 glutathione S-transferase theta 1 -2.84883 0.014633
STEAP4 STEAP family member 4 -2.51858 0.011631
NHLH2 nescient helix loop helix 2 -2.21331 0.001196
MAST4 Microtubule Associated Serine/Threonine Kinase Family Member 4 -2.06517 0.016778
KLHL24 kelch-like 24 (Drosophila) -2.05221 0.010495
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) -1.95113 0.033836
ARRDC3 arrestin domain containing 3 -1.84582 0.032566
LOC101928100 uncharacterized -1.83053 0.013417
PELI1 Pellino homolog 1 (Drosophila) -1.77824 0.045639
SLC28A3 solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 -1.77746 0.035360
Genes up-regulated in BCNS fibroblasts
TMEM155 transmembrane protein 155 2.61437 0.008088
ABAT 4-aminobutyrate aminotransferase 2.55331 0.011422
BEX1 brain expressed, X-linked 1 2.3517 0.027068
PDE4DIP phosphodiesterase 4D interacting protein 2.32946 0.035918
CPM carboxypeptidase M 2.27972 0.027836
HNMT histamine N-methyltransferase 2.25939 0.035685
SFRP2 secreted frizzled-related protein 2 2.25661 0.036160
AKR1C3 aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) 2.23228 0.046084
RAB27B RAB27B, member RAS oncogene family 2.14117 0.004020
PLAC8 placenta-specific 8 2.13321 0.011749
(Continued)
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relaxing the strict FDR cut-off, effected the unmasking of 
candidate genes that are differentially expressed at baseline 
in this hypothesis-generating analysis. The top up-regulated 
genes at baseline in keratinocytes derived from BCNS 
patients were NFIA-AS2, RBMY3AP, SEC16B, CROCC, 
SYN1, MKL1, FAM71A, LOC101928973, SIM2, GNG8 
in comparison to normal keratinocytes, whereas GSTT1, 
STEAP4, NHLH2, MAST4, KLHL24, MALAT1, ARRDC3, 
LOC101928100, PELI, SLC28A3 were the most down-
regulated genes (Table 2). The top up-regulated genes at 
baseline in BCNS fibroblasts were TMEM155, ABAT, BEX1, 
PDE4DIP, CPM, HNMT, SFRP2, AKR1C3, RAB27B, 
PLAC8, whereas GOLGA8A/GOLGA8B, NEAT1, MALAT1, 
MEG3, COL4A1, BCAT1, E2F7, FN1, LOC100190986, 
HELLS were the most down-regulated (Table 2). The 
ANOVA design and the comprehensive gene lists used for 
baseline comparison are provided in Supplementary File 1.
GSEA specifies baseline differences between 
BCNS and normal keratinocytes or fibroblasts
Next, we performed baseline gene set enrichment 
analyses (GSEA) of both keratinocytes and fibroblasts 
samples derived from BCNS patients and compared them 
to the control group (Figure 2). The results indicated a 
positive correlation of BCNS keratinocytes with predefined 
pancreatic β cell hallmark gene set that comprises 40 genes, 
specifically upregulated in pancreatic beta cells and known 
to be involved in glucose metabolism and dysglycemia 
(Figure 2A). Interestingly, BCNS keratinocytes, in contrast 
to normal keratinocytes, correlated negatively with the 
oncogenic gene signature mTOR_UP.N4.V1_DN in the 
MSigDb (Figure 2A and Supplementary File 2), comprising 
genes shown to be down-regulated upon treatment with 
rapamycin [48]. In the case of BCNS fibroblasts, compared 
with normal fibroblasts, GSEA pointed to a negative 
correlation with three oncogenic signatures in the MsigDb 
that comprised genes down-regulated in response to 
activated CTNNB1 overexpression (BCAT_BILD_ET_
AL_DN) and RNAi-mediated JAK2 knockdown (JAK2_
DN.V1_DN), and genes up-regulated upon RNAi-mediated 
knockdown of PCGF2 (MEL18_DN.V1_UP) (Figure 2B).
Biological differences attributed to rapamycin 
effects in BCNS and normal keratinocytes
Here we used GSEA algorithm on comprehensive 
microarray dataset without preprocessing to determine 
an a priori defined gene sets that exhibit statistically 
significant and biologically relevant differences between 
untreated and rapamycin treated BCNS keratinocytes and 
fibroblasts. The GSEA results indicated several significant 
pathways that were altered by rapamycin treatment in 
both BCNS keratinocytes and BCNS fibroblasts (Figure 
3, Supplementary Files 2–4).
In BCNS keratinocytes, enriched signatures in 
the presence of rapamycin signal the involvement of 
and regulation by MYC and G2/M checkpoint genes, 
cell cycle related targets of E2F transcription factor and 
mitotic spindle assembly [49]. The oncogenic signatures 
enriched in BCNS keratinocyte treated with rapamycin 
showed sets of genes up-regulated in neuronal precursors 
after Shh stimulation, PIGF treatment, genes governed 
by overexpression of E2F1 and E2F3, and genes up-
regulated in primary keratinocytes from RB1 and RBL1 
skin-specific knockout mice. Interestingly as well, the 
YAP conserved signature [49–51], was also shown to be 
concordant with rapamycin treated BCNS keratinocytes 
Gene Symbol Gene title (HGNC approved) Fold change p-value
Genes down-regulated in BCNS fibroblasts
GOLGA8A golgin A8 family, member A -2.88122 0.013547
NEAT1 Nuclear Paraspeckle assembly transcript 1 (non-protein coding) -2.37719 0.032147
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) -2.36124 0.023835
MEG3 maternally expressed 3 (non-protein coding) -2.34455 0.019488
COL4A1 collagen, type IV, alpha 1 -2.26454 0.022223
BCAT1 branched chain amino-acid transaminase 1, cytosolic -2.16931 0.018688
E2F7 E2F transcription factor 7 -2.16325 0.029640
FN1 fibronectin 1 -2.1232 0.027185
LOC100190986 hypothetical LOC100190986 -2.09273 0.022763
HELLS helicase, lymphoid-specific -2.08964 0.009022
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(Figure 3A, Supplementary Files 2–4). The oncogenic 
signatures comprising of down-regulated genes leading to 
CTNNB1 overexpression, SRC overexpression, oncogenic 
KRAS expression in context of TBK1 knockdown, RNAi 
mediated knockdown of genes such as EIF4G1, HOXA9 
and RPS14, and genes down-regulated after VEGFA 
treatment, positively correlated with BCNS keratinocytes 
after rapamycin treatment (data not shown).
Biological differences attributed to rapamycin 
effects in BCNS and normal fibroblasts
The GSEA pointed to genes upregulated by 
activation of PI3K/AKT/mTOR pathway and mTORC1 
complex, as well as genes involved in mitotic spindle 
assembly, DNA repair, G2/M checkpoint, and genes 
regulated by MYC which appear to be in agreement with 
Figure 2: Gene set enrichment analyses (GSEA) on BCNS keratinocytes and fibroblasts compared to normal samples. 
(A) GSEA shows that the ‘HALLMARK_PANCREAS_BETA_CELLS’ gene-set comprising of genes specifically up-regulated in pancreatic 
beta cells is enriched in BCNS keratinocytes as compared to the normal keratinocyte samples. The GSEA analysis also indicates that the 
‘MTOR_UP.N4.V1_DN’ gene set containing down-regulated genes post rapamycin treatment is enriched in the normal keratinocytes (A). 
(B) For the fibroblasts, GSEA shows that the ‘BCAT_BILD_ET_AL_DN’ gene set comprising of genes down-regulated due to activated 
CTNNB1 overexpression; the ‘MEL18_DN.V1_UP’ gene set comprising of up-regulated genes in medullablastoma cells after PCGF2 
knockdown; and the ‘JAK2_DN.V1_DN’ gene set containing the genes down-regulated by JAK2 knock-down are all enriched in the 
normal fibroblast samples. For the enrichment plots, profile of running ES score and position of GeneSet members on the rank ordered list 
are denoted for HALLMARK_PANCREAS_BETA_CELLS (A), MTOR_UP.N4.V1_DN (A), BCAT_BILD_ET_AL_DN (B), MEL18_
DN.V1_UP (B), JAK2_DN.V1_DN (B), and the respective normalized enrichment scores (NES), nominal p-values (NOM p-val), and 
q-values (FDR q-val) are summarized in table below the plots.
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Figure 3: Gene set enrichment analyses (GSEA) on rapamycin-treated BCNS keratinocytes and fibroblasts compared 
to normal samples. (A) GSEA shows that the ‘GCNP_SHH_UP_EARLY.V1_UP’ gene set consisting of genes up-regulated in granule 
cell neuron precursors (GCNP) after Shh stimulation for 3h are positively correlated and enriched in BCNS keratinocytes treated with 
rapamycin. Interestingly, GSEA also indicates the enrichment of a YAP conserved signature in the rapamycin treated BCNS keratinocytes. 
(B) For the fibroblasts, GSEA indicates that normal fibroblasts treated with rapamycin correlate with the hallmark gene sets namely 
‘GLYCOLYSIS’, ‘PI3K/AKT/MTOR SIGNALING’, and ‘MTORC1 SIGNALING’ as compared to rapamycin treated BCNS fibroblasts. 
For the enrichment plots, profile of running ES score and position of GeneSet members on the rank ordered list for are denoted for oncogenic 
signatures ‘GCNP_SHH_UP_LATE.V1_UP’ (A), CORDENONSI_YAP_CONSERVED_SIGNATURE’ (A), ‘GCNP_SHH_UP_EARLY.
V1_UP’ (A), and the hallmark gene sets namely ‘GLYCOLYSIS’ (B), PI3K/AKT/MTOR SIGNALING (B), MTORC1 SIGNALING (B) 
and the respective normalized enrichment scores (NES), nominal p-values (NOM p-val), and q-values (FDR q-val) are summarized in table 
below the plots.
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Table 3: List of top genes differentially regulated after rapamycin treatment in keratinocytes and fibroblasts derived 
from normal individuals
Gene Symbol Gene title (HGNC approved) Fold change p-value
Genes up-regulated in normal keratinocytes after rapamycin treatment
KLHL24 kelch-like family member 24 11.2986 0.000701
C5orf41 CREB3 regulatory factor 7.59837 0.000914
IRF6 interferon regulatory factor 6 7.09155 0.003863
ATF3 activating transcription factor 3 6.42457 6.31E-05
GPNMB glycoprotein (transmembrane) nmb 6.19196 0.000485
NEAT1 nuclear paraspeckle assembly transcript 1 (non-protein coding) 5.539 0.001790
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) 5.28172 0.000797
IRS2 insulin receptor substrate 2 4.58514 0.000667
DUSP10 dual specificity phosphatase 10 4.47873 0.000829
S100P S100 calcium binding protein P 4.22571 3.44E-09
Genes down-regulated in normal keratinocytes after rapamycin treatment
RRM2 ribonucleotide reductase M2 -13.9567 0.001023
DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) -12.2969 0.003649
CCNE2 cyclin E2 -10.7273 2.43E-05
UHRF1 ubiquitin-like with PHD and ring finger domains 1 -10.2451 0.000128
MCM10 minichromosome maintenance complex component 10 -9.9609 0.002114
CDC6 cell division cycle 6 -9.89019 0.002154
THBS1 thrombospondin 1 -8.83678 6.24E-05
SHCBP1 SHC SH2-domain binding protein 1 -7.3742 4.93E-06
DHFR dihydrofolate reductase -7.32771 0.004707
ZWINT ZW10 interactor -7.20764 0.001275
Genes up-regulated in normal fibroblasts after rapamycin treatment
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide 17.4006 7.18E-06
ITGB8 integrin, beta 8 6.98181 0.000417
DIO2 deiodinase, iodothyronine, type II 6.75995 5.31E-05
FGF7 fibroblast growth factor 7 5.35228 0.001493
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 5.18771 0.000186
GRIA1 glutamate receptor, ionotropic, AMPA 1 5.17074 9.47E-09
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 5.06774 0.000937
C13orf15 regulator of cell cycle 4.82343 7.65E-05
FMO2 flavin containing monooxygenase 4 (non-functional) 4.74587 2.43E-07
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 4.70169 1.93E-06
Genes down-regulated in normal fibroblasts after rapamycin treatment
ANLN anillin, actin binding protein -40.9022 6.14E-06
PBK PDZ binding kinase -38.6028 2.70E-06
(Continued)
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Gene Symbol Gene title (HGNC approved) Fold change p-value
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 -35.7893 7.76E-08
RRM2 ribonucleotide reductase M2 -34.5474 2.81E-06
HMMR hyaluronan-mediated motility receptor (RHAMM) -30.7856 1.68E-07
TOP2A topoisomerase (DNA) II alpha 170kDa -30.641 5.36E-07
SHCBP1 SHC SH2-domain binding protein 1 -30.4333 7.90E-09
CEP55 centrosomal protein 55kDa -29.9081 1.91E-09
TTK TTK protein kinase -29.053 1.60E-08
NDC80 NDC80 kinetochore complex component -28.6074 5.35E-08
Table 4: List of top genes differentially regulated after rapamycin treatment in keratinocytes and fibroblasts derived 
from BCNS individuals
Gene Symbol Gene title (HGNC approved) Fold change p-value
Genes up-regulated in BCNS keratinocytes after rapamycin treatment
KLHL24 kelch-like family member 24 7.63805 0.000303
GPNMB glycoprotein (transmembrane) nmb 5.38456 0.000811
ATF3 activating transcription factor 3 4.94199 0.000227
GABARAPL1 GABA(A) receptor-associated protein like 1 3.95871 0.000281
IRS2 insulin receptor substrate 2 3.88798 0.001592
JMY junction mediating and regulatory protein, p53 cofactor 3.36795 1.90E-06
ADCK3 aarF domain containing kinase 3 3.21844 9.14E-05
BIRC3 baculoviral IAP repeat containing 3 3.11232 0.000889
ZBTB10 zinc finger and BTB domain containing 10 3.02502 0.002266
NCRNA00219 EPB41L4A antisense RNA 1 2.94874 4.48E-07
Genes down-regulated in BCNS keratinocytes after rapamycin treatment
THBS1 thrombospondin 1 -5.00466 0.001087
GJB2 gap junction protein, beta 2, 26kDa -3.99488 0.001130
NAV3 neuron navigator 3 -3.86258 0.000239
ABAT 4-aminobutyrate aminotransferase -3.1763 1.41E-06
SHCBP1 SHC SH2-domain binding protein 1 -3.16137 0.001208
CDC25A cell division cycle 25A -3.08918 0.001806
CXCL14 chemokine (C-X-C motif) ligand 14 -2.93124 5.30E-06
SORL1 sortilin-related receptor, L(DLR class) A repeats containing -2.81784 0.001444
KRT1 keratin 1, type II -2.77983 0.001714
CDKN3 cyclin-dependent kinase inhibitor 3 -2.75698 0.000109
Genes up-regulated in BCNS fibroblasts after rapamycin treatment
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide 14.5357 9.23E-06
TXNIP thioredoxin interacting protein 6.7023 0.004666
ITGB8 integrin, beta 8 5.53155 0.001337
(Continued)
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the transcriptomic profiles of BCNS fibroblasts post 
rapamycin treatment (Figure 3B, Supplementary Files 3–4). 
Additionally, genes upregulated by APC knockout, RNAi 
mediated ELK3 knockdown in response to hypoxia, MYC 
and IRF4 targets, along with genes down regulated in 
lesional skin biopsies from mycosis fungoides patients 
compared to normal skin samples positively correlated 
with the results on treated BCNS fibroblasts. Oncogenic 
signatures comprising of up-regulated genes in primary 
keratinocytes from RB1 and RBL2 skin specific knockout, 
genes upregulated upon EED or EZH2 knockdown, 
MYC overexpression, stimulation with Shh, and genes 
upregulated by everolimus are found to be correlated with 
treated BCNS fibroblasts. Also, significant immunologic 
signatures were enriched in the treated BCNS fibroblasts.
Furthermore, GSEA indicated genes involved in 
glycogenesis and gluconeogenesis and genes upregulated 
by PI3K/AKT/mTOR pathway and mTORC1 complex 
activation, genes important for and involved in mitotic 
spindle assembly, DNA repair, G2/M checkpoint, genes 
responding to estrogen and genes regulated by MYC [49] 
were negatively correlated with the transcriptomic profiles 
of BCNS fibroblasts post rapamycin treatment. Additionally, 
genes expressed in multipotent progenitors, genes 
upregulated by APC or BCL3 knockout or RNAi mediated 
ELK3 knockdown in response to hypoxia, MYC and IRF4 
targets, along with genes downregulated in lesional skin 
biopsies from mycosis fungoides patients compared to 
normal skin samples and genes upregulated in peripheral 
blood monocytes of Sezary syndrome, were negatively 
correlated with rapamycin-treated BCNS fibroblasts. Also, 
oncogenic signatures comprising of YAP [50, 51] conserved 
signature, up-regulated genes in RB1 and RBL2 skin 
specific knockout primary keratinocytes, genes upregulated 
upon EED or EZH2 knockdown, MYC overexpression, 
stimulation with Shh, and genes upregulated by everolimus, 
were found to be negatively correlated with treated BCNS 
fibroblasts. Gene sets consisting of downregulated genes 
upon SRC overexpression, RPS14 knockdown, HOXA9 
knockdown, and VEGFA treatment were also negatively 
correlated with rapamycin treated BCNS fibroblasts. On 
other hand, significant immunologic signatures were 
enriched in untreated BCNS fibroblasts.
Ingenuity Pathway Analysis (IPA) shows distinct 
signaling pathways enriched in BCNS samples 
treated with rapamycin
To study whether rapamycin treatment affected 
cells derived from BCNS patients with PTCH1 mutation 
differently than normal samples, we generated a gene 
list of the top differentially regulated and statistically 
Gene Symbol Gene title (HGNC approved) Fold change p-value
GLDN gliomedin 5.28474 0.000403
DIO2 deiodinase, iodothyronine, type II 5.08305 0.000173
GRIA1 glutamate receptor, ionotropic, AMPA 1 4.61537 1.38E-08
FGF9 fibroblast growth factor 9 4.57488 0.002351
C13orf15 regulator of cell cycle 4.53467 7.38E-05
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 4.33477 2.99E-06
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 4.24931 0.002374
Genes down-regulated in BCNS fibroblasts after rapamycin treatment
ANLN anillin, actin binding protein -48.0347 4.14E-06
PBK PDZ binding kinase -45.1184 1.81E-06
KIF20A kinesin family member 20A -37.2298 2.83E-06
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 -36.5714 7.41E-08
CCNB1 cyclin B1 -35.2177 3.43E-06
RRM2 ribonucleotide reductase M2 -29.9324 4.66E-06
NDC80 NDC80 kinetochore complex component -25.8672 8.81E-08
CEP55 centrosomal protein 55kDa -25.5206 2.31E-09
BIRC5 baculoviral IAP repeat containing 5 -25.4299 1.16E-07
HMMR hyaluronan-mediated motility receptor (RHAMM) -25.2382 4.16E-07
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significant genes (cut-off p-value with FDR <0.05, FC>1.3 
or <-1.3), including the top genes as listed in Tables 3 
and 4 (the entire gene list is available in Supplementary 
File 4). Thus, a total of 4797 genes were differentially 
expressed in normal fibroblasts and expression of 3214 
genes were significantly altered in normal keratinocytes 
after rapamycin treatment. In the BCNS group, a total 
of 4959 genes and 1411 genes were differentially 
expressed in fibroblasts and keratinocytes, respectively 
after treatment with rapamycin. To tease out genes that 
were usually altered in both normal and BCNS groups 
following rapamycin treatment, we used Venn diagrams 
(Figure 4) to generate gene lists for further analysis.
IPA core analysis indicates effect of rapamycin 
treatment on keratinocyte and fibroblasts
Here we explored the genes/signaling pathways 
differentially expressed in response to rapamycin. To this 
end, we performed core IPA analysis on comprehensive 
Figure 4: Venn diagrams of genes commonly altered in both normal and BCNS group, with or without rapamycin 
treatment. Normal treated (Rx) samples were compared to normal control samples, and these samples were then compared BCNS treated 
(Rx) samples to BCNS control samples. (A) Keratinocyte samples. (B) Fibroblast samples.
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gene lists for fibroblasts and keratinocyte, including 
prioritized gene lists that were generated via the Venn 
diagram in Figure 4. The IPA core analysis showed 
enrichment of pathways that comprised mitotic role of Polo-
like Kinases, role of CHK proteins in cell cycle checkpoint 
control, ATM signaling, cell cycle control of chromosomal 
replication and role of BRCA1 in DNA damage response 
as top canonical pathways, based on focus genes present 
Figure 5: IPA core analysis indicates effect of rapamycin treatment on keratinocyte and fibroblasts. (A) Keratinocytes 
of healthy participants treated with rapamycin. (B) Keratinocytes of BCNS patients treated with rapamycin. (C) Fibroblasts of healthy 
participants treated with rapamycin. (D) Fibroblasts of BCNS patients treated with rapamycin.
Oncotarget1373www.oncotarget.com
Table 5A: Keratinocytes of healthy participants treated with rapamycin
Ingenuity Canonical Pathways -log(p-value) Molecules
Mitotic Roles of Polo-Like 
Kinase 5.6
PPP2R5E, KIF23, CHEK2, PPP2R4, CDC25A, PRC1, CDC20, PPP2R3A, 
CCNB2, KIF11, SMC3, PPP2R2A, WEE1, ANAPC11, PKMYT1, PLK4, 
ANAPC7, FZR1, CDC23, PLK1, CDK1, CCNB1, FBXO5
Role of CHK Proteins in Cell 
Cycle Checkpoint Control 5.53
SLC19A1, PPP2R5E, E2F5, BRCA1, RFC3, CHEK2, PPP2R4, 
CDC25A, MDC1, PPP2R3A, PPP2R2A, RAD1, RAD9A, RFC5, 
CDKN1A, RFC2, RFC4, ATMIN, PLK1, CDK1, CHEK1
ATM Signaling 4.97
JUN, BRCA1, CBX5, CREB1, CHEK2, CDC25A, GADD45B, 
MDC1, CCNB2, TDP1, SMC2, SMC3, FANCD2, RAD9A, CDKN1A, 
MAPK8, RAD51, GADD45G, CDK1, CCNB1, CHEK1
Cell Cycle Control of 
Chromosomal Replication 4.92
CDK7, CHEK2, MCM7, ORC6, ORC1, CDC45, RPA3, MCM3, 
MCM6, CDK6, MCM4, MCM5, CDC6
Role of BRCA1 in DNA Damage 
Response 4.87
RFC3, CHEK2, SMARCA4, MDC1, MSH6, RFC2, CDKN1A, 
FANCG, RBL1, RFC4, SLC19A1, E2F5, BRCA1, ATF1, SMARCE1, 
FANCM, FANCD2, BRD7, RFC5, ARID2, BRCA2, RAD51, PLK1, 
MSH2, CHEK1
Mismatch Repair in Eukaryotes 4.24 SLC19A1, FEN1, RFC3, EXO1, MSH6, RFC5, RFC2, RFC4, MSH2
Hereditary Breast Cancer 
Signaling 4.16
RFC3, AKT3, CHEK2, PIK3C2A, TUBG1, GADD45B, SMARCA4, 
PIK3CA, MSH6, RFC2, CDKN1A, FANCG, CDK6, RFC4, 
GADD45G, SLC19A1, BRCA1, PIK3R4, SMARCE1, FANCM, 
AKT2, WEE1, POLR2H, FANCD2, BRD7, RFC5, ARID2, BRCA2, 
RAD51, CDK1, CCNB1, MSH2, CHEK1
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 3.98
TOP2A, BRCA1, YWHAQ, CDK7, CHEK2, AURKA, PTPMT1, 
CCNB2, WEE1, PKMYT1, SKP2, CDKN1A, YWHAB, PLK1, CDK1, 
CCNB1, CHEK1
DNA damage-induced 14-3-3σ 
Signaling 3.49
CCNE2, BRCA1, AKT3, RAD9A, CCNB2, AKT2, RAD1, CDK1, 
CCNB1
Glioma Signaling 3.41
SOS2, AKT3, PIK3C2A, CALM1 (includes others), CAMK2D, 
PDGFB, PIK3CA, CDKN2D, CDKN1A, GRB2, SIN3A, PA2G4, 
RBL1, CDK6, E2F5, EGFR, PRKD3, PIK3R4, CAMK1D, AKT2, 
IGF1R, PRKCA, MAPK1, TFDP1, PRKCG
Ovarian Cancer Signaling 3.29
EDNRA, AKT3, PIK3C2A, WNT5A, FZD5, WNT11, PIK3CA, FZD1, 
MSH6, EDN1, SIN3A, PA2G4, WNT6, VEGFC, PRKAR2A, BRCA1, 
EGFR, TCF3, CGA, TCF4, PIK3R4, AKT2, CD44, BRAF, PTGS2, 
MAPK1, BRCA2, RAD51, TFDP1, MSH2, GJA1
3-phosphoinositide Degradation 3.15
DUSP10, PPP2R5E, NUDT1, MTMR4, NUDT3, PPM1F, PPP2R4, 
PPP2R3A, MTMR3, STYXL1, OCRL, INPP5D, DUSP23, DUSP1, 
PPIP5K1, SYNJ2, MTMR6, PXYLP1, INPP5F, PTPMT1, PTPN2, 
CDC25A, PTPRO, PAWR, DUSP2, ACP1, TMEM55B, NUDT4, 
HACD2, PPP1R13B, NUDT15, IGBP1
14-3-3-mediated Signaling 3.13
JUN, YWHAQ, AKT3, PIK3C2A, TUBB3, TUBG1, YAP1, TUBA1C, 
VIM, TUBA1A, SNCA, PIK3CA, GRB2, MAPK8, MAPT, YWHAB, 
FOXO1, TUBA3C/TUBA3D, PRKD3, PIK3R4, AKT2, TUBB4B, 
PRKCA, TUBA1B, MAPK1, TUBA4A, BAX, PRKCG
p53 Signaling 3.12
JUN, AKT3, TP53AIP1, CHEK2, PIK3C2A, GADD45B, THBS1, 
PIK3CA, CDKN1A, PLAGL1, MAPK8, GADD45G, BRCA1, TP63, 
PIK3R4, JMY, BIRC5, ST13, AKT2, CASP6, HIF1A, PPP1R13B, 
BAX, ADCK3, CHEK1
PDGF Signaling 3.11
JUN, EIF2AK2, SOS2, PIK3C2A, INPP5F, CRKL, PIK3R4, 
CSNK2A2, JAK1, PDGFB, CSNK2A1, ABL2, OCRL, INPP5D, 
PIK3CA, ACP1, PRKCA, MAPK1, GRB2, SYNJ2, MAPK8
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among the 3214 genes that are differentially regulated in 
normal keratinocytes in response to rapamycin (Figure 
5A, Table 5A). A Similar IPA core analysis of BCNS 
keratinocytes treated with rapamycin resulted in enrichment 
of PTEN signaling, Natural killer cell signaling, inhibition 
of angiogenesis by TSP1, p53 signaling and PI3K signaling 
in B lymphocytes as top canonical pathways, based on 
focus genes present in 1411 differentially regulated genes 
after rapamycin treatment (Figure 5B, Table 5B).
In the case of the normal fibroblasts, an IPA core 
analysis of 4797 differentially regulated genes in response 
to rapamycin resulted in enrichment of role of BRCA1 in 
DNA damage response, role of CHK proteins in cell cycle 
checkpoint control, mitotic roles of Polo-like Kinases, 
cell cycle control of chromosomal replication and protein 
ubiquitination pathway as canonical signaling pathways 
(Figure 5C, Table 5C). On the other hand, a core analysis 
of 4959 genes enriched in rapamycin treated BCNS 
fibroblasts pointed to top canonical pathways that included 
those playing a role of BRCA1 in DNA damage response, 
protein ubiquitination pathway, hereditary breast cancer 
signaling, cell cycle control of chromosomal replication 
and mitotic roles of Polo-like Kinases (Figure 5D, Table 
5D). Although it may appear that there was some overlap 
among canonical signaling pathways between normal and 
BCNS samples, the focus molecules in these pathways 
Table 5B: Keratinocytes of BCNS patients treated with rapamycin
Ingenuity Canonical Pathways -log(p-value) Molecules
PTEN Signaling 3.94
FGFR2, AKT3, INPP5F, BCL2L11, TGFBR3, CSNK2A2, AKT2, 
CSNK2A1, BMPR1B, H2BFM, OCRL, INPP5D, PIK3CA, 
CDKN1A, MAPK1, SYNJ2, ITGA4, TGFBR1
Natural Killer Cell Signaling 3.52
PIK3R6, AKT3, INPP5F, LILRB1, AKT2, VAV2, FYN, OCRL, 
INPP5D, PIK3CA, PRKCA, TYROBP, SH3BP2, MAPK1, SYNJ2, 
NCK1
Inhibition of Angiogenesis by TSP1 3.46 JUN, FYN, AKT3, MMP9, MAPK1, TGFBR1, THBS1, AKT2
p53 Signaling 3.36 JUN, PIK3R6, AKT3, TP53AIP1, JMY, BIRC5, ST13, THBS1, AKT2, PIK3CA, CDKN1A, PLAGL1, BAX, ADCK3, CHEK1
PI3K Signaling in B Lymphocytes 3.2
JUN, AKT3, IRS2, CD79B, CHP1, ATF6, AKT2, PPP3CC, VAV2, 
ATF3, MALT1, FYN, INPP5D, PIK3CA, PLEKHA3, MAPK1, 
SH2B2
Insulin Receptor Signaling 2.62 PIK3R6, AKT3, IRS2, INPP5F, SCNN1A, AKT2, H2BFM, FYN, OCRL, INPP5D, PIK3CA, GYS1, MAPK1, SYNJ2, SH2B2, NCK1
Fc Epsilon RI Signaling 2.55 PIK3R6, AKT3, INPP5F, AKT2, VAV2, FYN, OCRL, INPP5D, PIK3CA, PRKCA, MAPK1, SYNJ2, PLA2G12A, PLA2G4A
Antiproliferative Role of TOB in T 
Cell Signaling 2.53 SMAD2, SKP2, MAPK1, CCNA2, TGFBR1, SMAD4
1D-myo-inositol Hexakisphosphate 
Biosynthesis II (Mammalian) 2.44 OCRL, INPP5D, INPP5F, ITPKB, SYNJ2
D-myo-inositol 
(1,3,4)-trisphosphate Biosynthesis 2.44 OCRL, INPP5D, INPP5F, ITPKB, SYNJ2
DNA damage-induced 14-3-3σ 
Signaling 2.44 AKT3, CCNB2, AKT2, RAD1, CCNB1
HER-2 Signaling in Breast Cancer 2.42 H2BFM, PIK3R6, AKT3, ITGB5, PIK3CA, ITGB6, PARD3, PRKCA, PARD6G, CDKN1A, AKT2
EGF Signaling 2.37 JUN, PIK3R6, AKT3, PIK3CA, PRKCA, CSNK2A2, MAPK1, AKT2, CSNK2A1
PDGF Signaling 2.37 JUN, PIK3R6, OCRL, INPP5D, PIK3CA, INPP5F, PRKCA, CSNK2A2, MAPK1, SYNJ2, CSNK2A1
Docosahexaenoic Acid (DHA) 
Signaling 2.22 H2BFM, PIK3R6, AKT3, PIK3CA, APP, BAX, AKT2
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Table 5C: Fibroblasts of healthy participants treated with rapamycin
Ingenuity Canonical Pathways -log(p-value) Molecules
Role of BRCA1 in DNA Damage 
Response 10.1
RFC3, FANCB, PBRM1, ATRIP, E2F1, BARD1, SMARCA4, MDC1, 
E2F3, NBN, TOPBP1, STAT1, MSH6, RFC2, FANCG, RPA1, RBL1, 
RFC4, MRE11A, SLC19A1, BRCA1, BRE, BRCC3, HLTF, FANCM, 
SMARCC2, RBBP8, BLM, BRIP1, RFC1, FANCD2, RFC5, FANCA, 
GADD45A, BRCA2, RAD51, ARID1A, PLK1, MSH2, CHEK1
Role of CHK Proteins in Cell 
Cycle Checkpoint Control 10.1
RFC3, E2F1, PPP2R3B, CLSPN, MDC1, PPP2R3A, E2F3, PCNA, 
PPP2R5C, CDC25C, NBN, RAD9A, RFC2, RPA1, PPP2CB, 
RFC4, MRE11A, PPP2CA, SLC19A1, BRCA1, CDC25A, CDK2, 
PPP2R2A, RAD1, HUS1, RFC1, RFC5, PPP2R5D, RAD17, PLK1, 
CDK1, CHEK1
Mitotic Roles of Polo-Like Kinase 8.76
KIF23, SMC1A, ESPL1, PPP2R3B, PPP2R3A, CCNB2, KIF11, 
ANAPC1, PPP2R5C, CDC25C, ANAPC5, PKMYT1, PPP2CB, 
HSP90AA1, PPP2CA, CDC27, CDC25A, PRC1, CDC20, PPP2R2A, 
CDC7, RAD21, PPP2R5D, PLK4, PLK2, HSP90AB1, PTTG1, FZR1, 
PLK1, CDK1, CCNB1, FBXO5, CDC25B
Cell Cycle Control of 
Chromosomal Replication 7.22
MCM7, MCM2, CDK2, ORC6, DBF4, CDC7, ORC1, CDC45, RPA1, 
RPA3, MCM3, MCM6, CDT1, CDK6, MCM4, MCM5, CDC6, ORC3
Protein Ubiquitination Pathway 6.2
HSPA2, UBE2M, DNAJC5, PSMD6, SMURF2, USP7, ANAPC1, 
HSPB2, ANAPC5, USP1, USP46, PSMA7, DNAJC9, UBE2V2, 
UCHL5, PSMB2, PSMA1, TRAF6, TCEB2, UBE2L3, UBE2H, 
USP14, UBE2G2, PSMA6, UBE2V1, PSME1, PSMD12, DNAJC18, 
UBE2J2, PSMC5, SUGT1, PSMD1, USP13, DNAJB11, UBE2C, 
HLA-C, HLA-B, NEDD4L, USP47, USP19, DNAJA1, DNAJB13, 
DNAJC11, THOP1, HSPD1, DNAJC4, USP5, PSME2, CBL, 
PSMD11, UBE2S, PSMD9, TCEB1, PSMD14, PSMC1, USP24, 
PSMD2, HSP90AA1, UBE2R2, BRCA1, HSPB11, UCHL1, PSMC3, 
UBR1, UBE2N, CDC20, USP10, HSPA4, NEDD4, UBE2B,HLA-A, 
UBE2L6, UBE2I, UCHL3, PSMD13, DNAJB4, HSP90AB1, FZR1, 
USP53
RAN Signaling 5.82 KPNA1, CSE1L, RANGAP1, KPNA2, XPO1, RCC1, KPNA3, IPO5, KPNA6, RAN, RANBP1, KPNB1
Mismatch Repair in Eukaryotes 5.82 SLC19A1, RFC1, FEN1, RFC3, EXO1, MSH6, RFC5, RFC2, RPA1, RFC4, PCNA, MSH2
Hereditary Breast Cancer 
Signaling 4.97
RFC3, FANCB, PBRM1, HDAC8, TUBG1, E2F1, BARD1, 
SMARCA4, PIK3R1, H2AFX, CDC25C, NBN, MSH6, RFC2, 
FANCG, RPA1, CDK6, RFC4, NPM1, MRE11A, SLC19A1, BRCA1, 
HDAC2, PIK3R3, POLR2E, HLTF, FANCM, SMARCC2, BLM, 
RFC1, FANCD2, POLR2D, RFC5, CCND1, FANCA, GADD45A, 
BRCA2, RAD51, HRAS, ARID1A, CDK1, CCNB1, MSH2, CHEK1
Remodeling of Epithelial 
Adherens Junctions 4.94
IQGAP1, ACTR2, VCL, TUBB3, TUBB6, MAPRE1, TUBG1, HGS, 
TUBA1C, ARPC5L, APC, DNM1L, TUBA1A, MET, TUBA3C/
TUBA3D, ARPC1A, CTNNA1, TUBB, ACTN1, NME1, TUBB4B, 
ARPC2, DNM2, RALA, TUBA1B, TUBA4A, ARF6
ATM Signaling 4.15
JUN, BRCA1, CBX5, SMC1A, CDK2, CDC25A, MDC1, CCNB2, 
TDP1, SMC2, H2AFX, CDC25C, NBN, BLM, TRIM28, FANCD2, 
RAD9A, MAPK8, GADD45A, RAD51, MRE11A, CDK1, CCNB1, 
CHEK1
(Continued)
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Ingenuity Canonical Pathways -log(p-value) Molecules
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 4.1
TOP2A, BRCA1, YWHAQ, YWHAG, AURKA, CKS2, CCNB2, 
YWHAH, CDC25C, BORA, PKMYT1, GADD45A, CKS1B, HIPK2, 
PRKDC, YWHAZ, PLK1, CDK1, CCNB1, CHEK1, CDC25B
Granzyme B Signaling 3.87 PARP1, APAF1, LMNB1, ENDOG, DFFA, PRKDC, CYCS, LMNB2, NUMA1, CASP8
Neuregulin Signaling 3.68
SOS2, ERBB2IP, ITGA2, PIK3R1, PTPN11, STAT5A, GRB2, DCN, 
CRK, HSP90AA1, PSEN1, RPS6KB2, TGFA, HBEGF, EGFR, 
PIK3R3, NRG1, RNF41, SOS1, PLCG2, PDPK1, DLG4, PRKCA, 
MAPK1, ITGA4, PLCG1, HSP90AB1, STAT5B, HRAS, ITGA5
DNA dsBreak Repair by 
Homologous Recombination 3.66
BRCA1, POLA1, GEN1, RPA1, LIG1, BRCA2, RAD51, MRE11A, 
NBN
Regulation of Cellular Mechanics 
by Calpain Protease 3.39
EGFR, TLN1, VCL, ITGA2, EZR, CDK2, PXN, ACTN1, TLN2, 
PTK2, CAPN5, CCND1, MAPK1, GRB2, ITGA4, CCNA2, CDK6, 
HRAS, ITGA5, CDK1, CAPN2
Table 5D: Fibroblasts of BCNS patients treated with rapamycin
Ingenuity Canonical Pathways -log(p-value) Molecules
Role of BRCA1 in DNA Damage 
Response 9.59
POU2F1, RFC3, FANCB, PBRM1, ATRIP, BARD1, SMARCA4, 
SMARCB1, NBN, DPF1, STAT1, MSH6, RFC2, FANCG, RPA1, 
RBL1, RFC4, MRE11A, SLC19A1, BRCA1, SMARCD1, BRE, 
MLH1, BABAM1, BRCC3, HLTF, SMARCE1, FANCM, SMARCC2, 
RBBP8, BRIP1, FANCD2, RFC5, FANCA, GADD45A, BRCA2, 
RAD51, PLK1, MSH2, CHEK1
Protein Ubiquitination Pathway 9.27
HSPA2, HSPA1L, UBE2M, PSMD3, DNAJC5, PSMD6, SMURF2, 
PSMB5, ANAPC1, PSMC4, ANAPC5, USP1, USP46, PSMA7, 
DNAJC9, PSMB7, UBE2V2, UCHL5, PSMA2, PSMB2, UBE2A, 
PSMA1, USP32, TRAF6, UBE2L3, PSMA4, UBE2H, USP14, UBE2G2, 
PSMA6, HSPB8, UBE2V1, PSME1, DNAJB5, PSMC2, PSMD12, 
DNAJC18, UBE4A, UBE2J2, PSMC5, SUGT1, PSMD1, USP13, 
UBE2C, HLA-C, HLA-B, RBX1, USP47, DNAJA1, DNAJB13, 
PSMD7, MED20, THOP1, HSPD1, DNAJB12, DNAJC4, USP5, 
PSME2, CBL, PSMD11, UBE2S, PSMD4, PSMD9, TCEB1, PSMD14, 
PSMC1, PSMB3, PSMD2, PSMD5, UBE2R2, PSMA5, BRCA1, 
HSPB11, PSMC3, UBR1, UBE2N, CDC20, USP10, HSPA4, USP39, 
NEDD4, HLA-A, UBE2D2, UCHL3, PSMD13, DNAJB4, PSMD8, 
PAN2, FZR1, USP53
Hereditary Breast Cancer 
Signaling 7.93
RFC3, HDAC8, TUBG1, POLR2F, BARD1, SMARCA4, POLR2K, 
SMARCB1, NBN, DPF1, RPA1, RFC4, MRE11A, HDAC1, 
SLC19A1, PIK3R3, SMARCD1, POLR2E, MLH1, HLTF, SMARCE1, 
SMARCC2, NRAS, FANCD2, POLR2D, CCND1, FANCA, 
GADD45A, BRCA2, MSH2, FANCB, PBRM1, PIK3R1, H2AFX, 
CDC25C, MSH6, RFC2, FANCG, CDK6, NPM1, BRCA1, HDAC2, 
SFN, RRAS2, FANCM, POLR2H, RFC5, RAD51, HRAS, CCNB1, 
CDK1, CHEK1
Cell Cycle Control of 
Chromosomal Replication 7.92
MCM7, MCM2, CDK2, ORC6, CDK5, DBF4, CDC7, ORC1, CDC45, 
RPA1, RPA3, MCM3, MCM6, CDT1, CDK6, MCM4, MCM5, CDC6, 
ORC3
(Continued)
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were different which would affect the direction of the 
pathway. BCNS keratinocytes had the most distinct 
canonical pathway signaling. The p-values and molecules 
for top canonical pathways are shown (Table 5A–5D); a 
comprehensive list is shown in Supplementary File 5.
In order to understand how canonical pathways 
that are uniquely enriched in normal or BCNS specimens 
respond differently to rapamycin due to differentially 
regulated genes, we dissected the gene list guided by the 
Venn diagram (Figure 4) and performed core analysis 
on each group. The canonical pathways enriched in both 
normal and BCNS keratinocytes, based on 812 common 
genes, were p53 signaling, DNA damage induced 14-3-
3 signaling, EGF signaling, IL-3 signaling and PTEN 
signaling. The IPA core analysis of the 812 differentially 
regulated genes common to both BCNS and normal 
keratinocytes after rapamycin treatment predicted 
CDKN1A, KDM5B, let-7 and PTEN to be activated 
Ingenuity Canonical Pathways -log(p-value) Molecules
Mitotic Roles of Polo-Like 
Kinase 6.44
KIF23, TGFB1, SMC1A, ESPL1, PPP2R4, PPP2R3A, CCNB2, KIF11, 
ANAPC1, PPP2R5C, CDC25C, ANAPC5, PKMYT1, ANAPC7, 
PPP2CA, CDC27, CDC25A, PRC1, CDC20, CDC7, RAD21, PPP2R5D, 
PLK4, PLK2, PTTG1, FZR1, PLK1, CDK1, CCNB1, FBXO5
Mismatch Repair in Eukaryotes 5.64 SLC19A1, FEN1, RFC3, EXO1, MSH6, RFC5, RFC2, RPA1, MLH1, RFC4, PCNA, MSH2
Role of CHK Proteins in Cell 
Cycle Checkpoint Control 4.48
SLC19A1, BRCA1, RFC3, PPP2R4, CDK2, CDC25A, CLSPN, 
PPP2R3A, PCNA, CDC25C, HUS1, PPP2R5C, NBN, RAD9A, RFC5, 
RFC2, PPP2R5D, RPA1, RFC4, MRE11A, PLK1, CDK1, PPP2CA, 
CHEK1
DNA dsBreak Repair by 
Homologous Recombination 4.47
BRCA1, POLA1, RAD52, GEN1, RPA1, LIG1, BRCA2, RAD51, 
MRE11A, NBN
Systemic Lupus Erythematosus 
Signaling 4.42
SNRPB2, LSM2, SNRNP40, SNRPD1, HNRNPC, FCER1G, LSM12, 
PRPF19, SNRNP25, SNRPA, PIK3R3, LSM8, HLAG, PRPF3, LSM1, 
NRAS, PRPF38A, HLA-C, HLA-B, PRPF31, JUN, PIK3R1, CBL, 
IL37, SNRNP200, LSM5, SNRPA1, PRPF8, SNRNP27, GRB2, 
IGHG1, LSM14B, SNRPG, NFATC4, HLA-E, RRAS2, SNRPE, 
SNRPC, PRPF4, LSM4, SOS1, SART1, SNRPN, HLA-A, NHP2L1, 
SNRPF, TXNL4A, MAPK1, PRPF40A, EFTUD2, SNRPD3, HRAS, 
LSM3, ZCRB1, HNRNPA2B1, PPIH, SNRPB
Oncostatin M Signaling 4.24
MT2A, RRAS2, PLAU, SOS1, OSMR, NRAS, MMP3, STAT3, 
STAT1, STAT5A, TIMP3, MAPK1, GRB2, EPAS1, STAT5B, HRAS, 
MMP1
Mitochondrial Dysfunction 3.89
VDAC3, ATP5F1, COX5A, MAPK10, MTND2, SDHB, NDUFA8, 
NDUFAB1, NDUFA9, SDHD, ATP5C1, BACE1, ATP5B, SDHC, 
UQCRC1, HTRA2, APP, NDUFB8, CPT1B, CYCS, VPS9D1, CYC1, 
SOD2, PRDX5, NDUFS6, AIFM1, MAOB, ATP5G3, COX11, 
VDAC1, COX7A1, CPT1A, GLRX2, NDUFV3, PRDX3, GPX4, 
NDUFA6, NDUFV2, MAOA, PSEN1, HSD17B10, ATP5G1, SURF1, 
PDHA1, NDUFS1, NDUFB6, CYB5A, NDUFA3, ATP5J2, COX7C
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 3.86
TOP2A, BRCA1, YWHAQ, SFN, YWHAG, AURKA, YWHAE, 
CKS2, CCNB2, YWHAH, CDC25C, BORA, PKMYT1, GADD45A, 
CKS1B, PRKDC, YWHAZ, PLK1, CDK1, CCNB1, CHEK1
HIPPO signaling 3.78
PPP1CC, YWHAQ, PARD3, PPP2R4, PPP2R3A, SMAD4, YWHAE, 
YWHAH, PPP2R5C, LLGL1, CSNK1D, PPP1R14B, ITCH, MOB1A, 
PPP2CA, CSNK1E, SFN, NF2, YWHAG, PPP1R12A, PPP1CA, 
TJP2, WWTR1, CD44, DLG4, RASSF1, PPP1CB, PPP2R5D, SAV1, 
YWHAZ, STK4
RAN Signaling 3.73 KPNA1, CSE1L, RANGAP1, KPNA2, KPNA3, IPO5, KPNA6, RAN, RANBP1, KPNB1
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Figure 6: Networks enriched in normal cells after rapamycin treatment. (A) Keratinocytes and (B) fibroblasts. Gene expression 
variation by at least 2-fold is depicted by color (red, up-regulated; green, down-regulated; gray, no significant change).
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Figure 7: Networks enriched in BCNS cells after rapamycin treatment. (A) Keratinocytes and (B) fibroblasts. Gene expression 
variation by at least 2-fold is depicted by color (red, up-regulated; green, down-regulated; gray, no significant change).
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upstream regulators while CSF2 to be inhibited. The 
regulator networks associated with IDs correspond to 
diseases and function namely cell death of squamous 
cell carcinoma cell lines. The top up-regulated molecules 
were ATF3, GPNMB, KLHL24, IRS2, S100P, OTUD1, 
GABARAPL3, HIST3H2A, EPB41L4A-AS1, LIMA1, 
TIAM2, JMY and ADCK3. The top down-regulated 
molecules are THBS1, SHCBP1, CDC25A, NAV3, 
ZNF367, ABAT, NCAPG, PLAGL1, TTK, GJB2, 
CXCL14, SORL1, CDKN3, RAB7B.
The canonical pathways enriched in normal 
keratinocytes only, based on 2402 genes analyzed, were 
mitotic roles of polo-like kinases, mismatch repair in 
eukaryotes, role of CHK proteins in cell cycle checkpoint 
control, role of BRCA1 in DNA damage response and 
cell cycle control of chromosomal replication. The top 
up-regulated molecules only in normal keratinocytes are 
KLHL24, CREBRF, IRF6, NEAT1, MALAT1, DUSP10, 
TXNIP, DDX6, CITED2, ZMAT3. The top down-
regulated molecules are RRM2, DTL, CCNE2, UHRF1, 
MCM10, CDC6, DHFR, ZWINT, GINS2, PTGS2 in 
normal keratinocytes in response to rapamycin. It is of 
interest that although the upstream regulator E2F4 has 
no activation prediction, TP53, NUPR1, let-7 and RB1 
are predicted to be active upstream regulators in normal 
keratinocytes.
Hepatic fibrosis/hepatic stellate cell activation, 
HIPPO signaling, natural killer cell signaling, galactose 
degradation (Leloir Pathway) and ILK signaling were 
identified as the top canonical pathways unique to the 
599 focus genes in the BCNS keratinocytes samples after 
rapamycin treatment. The top up-regulated molecules were 
BIRC3, ZBTB10, IFITM1, GART, CDK19, PLEKHM3, 
RSF1, FN1, ZCCHC7, TGFBR3. The top down-regulated 
molecules were KRT1, CLCA2, ARTN, TPM4, VPS53, 
S100A8, ACOT11, HDHD2, FKBP5, GNG8. The 
upstream regulators inhibited in the BCNS keratinocytes 
samples were microRNAs miR-1-3p (no activation score), 
miR-381-3p, miR-19b-3p, miR-19b-3p, miR-374b-5p, 
miR-340-5p. JNK signaling and miR-101-3p regulator 
network was predicted to be associated with the signaling 
response of BCNS keratinocytes to rapamycin.
Similar analysis of fibroblast samples that was 
based on 3496 differentially expressed genes common to 
both normal and BCNS fibroblasts resulted in enrichment 
of canonical pathways involving cell cycle control of 
chromosomal replication, role of BRCA1 in DNA damage 
response, mitotic roles of Polo-like kinase, hereditary 
breast cancer signaling and role of CHK proteins in Cell 
cycle checkpoint control. The top up-regulated molecules 
are ADH1B, ITGB8, DIO2, EFEMP1, GRIA1, SLC40A1, 
RGCC, FMO2, SVEP1, CCL2, GLDN, RGCC, STEAP4, 
DAPK1. The top down-regulated molecules were ANLN, 
PBK, DLGAP5, RRM2, HMMR, TOP2A, SHCBP1, 
CEP55, TTK, NDC80, KIF20A, CCNB1, BIRC5. In 
both normal and BCNS fibroblasts samples, upstream 
regulators CDKN1A and TP53 were activated whereas 
the E2F1 and RABL6 were predicted to be inhibited 
in response to rapamycin. It is of interest to note that 
RABL6 plays a role in cell growth and survival and its 
overexpression is associated with tumorigenesis.
The canonical pathways enriched in the normal 
fibroblast samples, based on 1301 unique genes, included 
CHK proteins in cell cycle checkpoint control, neuregulin 
signaling, PPAR/RXR activation, role of BRCA1 in 
DNA damage response and VEGF signaling. The top 
up-regulated molecules were FGF7, SPIDR, SFRP2, 
SYNPO2, FMO3, FAM198B, WISP1, IL6, CEBPD, 
JAM2. The top down-regulated molecules were HAS2, 
TMPO, C4orf46, USP1, MIS18BP1, HMGB2, NETO2, 
PSAT1, BLM, TRIM59. In the normal fibroblasts samples, 
upstream regulators miR-495-3p, miR-381-3p, miR-124-
3p, miR-590-3p, miR-340-5p were predicted to be active.
Based on 1463 unique genes differentially 
regulated in the BCNS fibroblasts only, mitochondrial 
dysfunction, oxidative phosphorylation, agrin interactions 
at neuromuscular junction, regulation of actin-based 
motility by Rho and estrogen receptor signaling were 
enriched canonical pathways. The top up-regulated 
molecules were TXNIP, FGF9, WISP2, TMTC1, ZBTB16, 
NEAT1, SEMA5A, IGF2, LRRN4CL, KCND3. The top 
down-regulated molecules were THBD, PHLDA1, TJP2, 
PRPS1, SRSF3, C4orf32, MATN2, ATOH8, EGR1, 
MLLT11. In the BCNS fibroblasts samples, the upstream 
regulators RICTOR and miR-22-3p ((miRNAs w/seed 
AGCUGCC) were activated. The upstream regulator 
1,2-dithiol-3-thione was predicted to be inhibited whereas 
no prediction for HNF4A and miR-9-5p (and other 
miRNAs w/seed CUUUGGU). The top regulator effects 
networks were associated with FLI1, MMP3, CD3 and 
NFE2L2. These analyses showed involvement of different 
focus molecules in different cell type that contribute to 
the same canonical pathways hinting to common signaling 
pathways (Supplementay File 5).
Networks enriched in BCNS samples after 
rapamycin treatment
Here we performed an IPA network analysis 
that revealed several important such networks that are 
significantly altered post-rapamycin treatment (Figures 
6 and 7). The most notably altered pathway in BCNS 
keratinocytes compared with normal keratinocytes, based 
on 35 focus molecules (score 50), was linked to digestive 
system development and function (Figure 6A and 7A). 
Several genes such as APP, SPON1 (cell adhesion 
promotes neurite growth and axonal guidance), CISD2 
(associated with neurodegenerative Wolfram syndrome 
2), KLK9 (associated with collagen biosynthesis and 
modification), CDCA3 (involved in cell cycle regulation 
mediated by APC) were included in this network and are 
related to development, neuronal growth and function.
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Similar analyses of BCNS and normal fibroblasts, 
based on 35 focus molecules, showed enrichment 
of networks related to cell cycle, DNA replication, 
recombination and repair (Figure 6B and 7B). Notably, 
CASC5 (kinetochore-microtubule attachment and 
chromosome segregation, MAPK1 (involved in 
proliferation, differentiation, transcriptional regulation), and 
CROCC (centrosome cohesion before mitosis, associated 
with medulloblastoma) were included in this network.
DISCUSSION
The cellular mechanisms whereby hedgehog (HH) 
pathway activation leads to BCCs are yet to be established 
[29]. Excess HH signaling may directly cause proliferation 
of BCC precursors [9, 52]. Alternatively, the HH pathway 
may be involved primarily in stem cell maintenance as 
has been shown in tumor stem cells for some tissues 
[8, 53, 54]. As either a direct effector of proliferation or 
maintainer of stem cells, HH would be acting in a cell 
autonomous role in BCCs. An alternative model involves 
a paracrine function in which HH signaling acts upon 
stroma to generate a tumor-promoting microenvironment 
while having a modest role in the tumor cells themselves 
[44, 45]. This model is appealing in the case of BCCs 
because of evidence that conditioned stroma is necessary 
for maintenance of tumor viability and growth. There 
are data supporting all three of these biological roles in 
cancer, and it is not clear which may apply to epidermal 
cell transformation [29]. Likewise, the fine details of the 
molecular mechanisms by which HH pathway activation 
exerts its effects are not entirely understood. Most 
investigations have focused on downstream targets of the 
GLI transactivators. A number of specific candidate genes 
have been studied in human and mouse BCCs including 
PDGF receptor, BCL2, cyclin D1 and D2. However, 
unbiased attempts by global gene expression to determine 
key HH target genes important in BCCs have yielded 
inconsistent results (reviewed in [22]).
Using exploratory analysis at baseline, we 
were unable to identify gene expression changes that 
molecularly distinguish affected individuals from controls. 
The lack of clear delineation of BCNS subjects from 
normal controls is depicted by PCA and HC analyses 
of fibroblasts or keratinocytes (Supplementary Figure 1 
and Figure 1). Our results showing lack of BCNS sample 
clustering on the basis of mutation type or gender are in 
line with previous observations demonstrating lack of 
evidence for genotype-phenotype correlation in BCNS 
cases, including no association between mutation type, 
age of onset, or number of BCCs developed in BCNS 
patients [55]. Conceivably, subtle gene expression 
changes caused by single copy loss of PTCH1 may 
enable the intact PTCH1 gene to exert negative feedback 
control, particularly under in vitro growth conditions. 
Along these lines, previous studies showed that the up-
regulated HH-signaling in vivo was suppressed in BCC 
and medulloblastoma (MB) cells grown in vitro [46, 
47]. Moreover, HH signaling of MB cells grown in vitro 
was not restored upon transplantation in nude mice, nor 
did they respond to treatment with HH antagonists [47]. 
It is also interesting to consider whether apart from the 
classical tumor suppressor ‘two-hit’ model, the ‘continuum 
model’ [56] that accounts for subtle dosage effects, 
‘obligate haploinsufficiency’, is associated with the effect 
of PTCH1 tumor suppressor gene in BCNS.
Hence, our results at low stringency (p-value <0.05, no 
FDR cut-off; FC 1.3) have enabled us to unmask candidate 
baseline differences between BCNS and normal control cells 
that are likely to play a role in BCC growth under conditions 
in which the HH pathway has been suppressed [47]. Thus, 
a total of 585 and 857 genes differentially expressed in 
keratinocytes and fibroblasts samples from BCNS subjects, 
respectively were identified. For example, a Gene Set 
Enrichment Analysis (GSEA) of highly regulated candidate 
genes recognized pancreatic β cell hallmark genes and mTOR 
signaling genes in BCNS keratinocytes, whereas analyses of 
BCNS fibroblasts candidate genes showed gene signatures 
that affect pathways regulating pluripotency of stem cells, 
including the WNT pathway. Moreover, these differentially 
affected gene signatures included canonical and non-canonical 
HH pathways in BCNS keratinocytes and fibroblasts that are 
likely to play a role in BCC development. One such example 
that is likely relevant in this context is our finding that MKL1 
is up-regulated in BCNS keratinocytes, since its activation 
within the non-canonical HH pathway has recently been 
shown to promote drug resistance of BCCs [57].
Importantly, the phenotypic features of BCNS 
patients shown in our study and elsewhere [4, 58–61], 
provide strong support for a two-hit mechanism wherein 
the first hit is associated with early molecular changes and 
a variety of developmental defects occurring concurrently. 
While some of these defects may in fact arise through 
a two-hit mechanism, it is difficult to imagine how 
such symmetric features as generalized overgrowth, 
macrocephaly, coarse facies, and hypertelorism could arise 
through any mechanism other than one invoking an effect 
of haploinsufficiency. Hence, gene expression patterns 
in tissues at some stages of development must almost 
certainly differ between BCNS subjects and controls. 
Accordingly, networks of differentially regulated genes 
at baseline shown here are of interest as they were found 
to be enriched in processes which might play important 
roles in the development of congenital phenotype 
(e.g., macrocephaly, skeletal abnormalities, bossing 
of forehead). For example, BEX1 (Brain Expressed, 
X-Linked 1) plays a role in cell cycle progression and 
neuronal differentiation, and is related to p75NTR/
NGFR-mediated signaling and it inhibits neuronal 
differentiation in response to nerve growth factor (NGF). 
SOX4 (SRY-related HMG-box) is a member of SOX 
family of transcription factors that regulate pathways in 
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embryonic development and cell fate determination and is 
related to ERK signaling. MEG3 (Maternally Expressed 
3) may function as a lncRNA tumor suppressor as it 
inhibit tumor cell proliferation, interacts and regulates 
p53 gene expression and its down-regulation has been 
experimentally observed in cancer cell lines of various 
origins. SYN1 (Synapsin 1) is member of neuronal 
phosphoproteins that function to regulate axonogenesis 
and synaptogenesis. SIM2 (Drosophila single-minded 
gene homolog) encodes for transcription factor that 
regulates neurogenesis and may have pleiotropic effects in 
tissues during development. Thus, perturbations caused by 
loss of function PTCH1 mutations although subtle, seem 
sufficient to result in developmental anomalies and BCCs 
in BCNS patients. The occurrence of PTCH1 mutations 
that result in developmental anomalies concomitant with 
BCC expression serve as poignant reminder of the role 
of PTCH in normal tissue development and as a tumor 
suppressor gene (TSG), a basic tenet in cancer biology, 
including all TSGs identified to date [62].
Prior studies suggest that signaling through the 
hedgehog and mTOR pathways have separate, albeit 
synergistic effects on malignant transformation [33–35, 
37]. Indeed, our present GSEA studies (vide supra) 
showed an activated mTOR pathway in BCNS PTCH1 
(+/-) keratinocytes. Accordingly, mTOR/S6K1 and HH 
pathways coincidentally target an overlapping set of genes 
that are key modulators of HH-related carcinogenesis 
[38–40]. In this regard, a recent study has demonstrated 
the inhibition of human rhabdomyosarcoma xenografts by 
rapamycin through its effect on HH effector genes such as 
Gli1 and Gli 2 as well as PTCH1 and PATCH2 [63]. These 
effects were associated with over 80% reduction in cyclin 
D1, a downstream transcription target for both HH and 
mTOR signaling pathways [63].
To investigate the differential effect of rapamycin 
in BCNS, we compared the gene expression profiles of 
keratinocytes and fibroblasts derived from normal subjects 
and from unaffected skin cells of BCNS patients. Accordingly, 
rapamycin affected the expression of 1411 genes and 3214 
genes which were altered in BCNS and normal keratinocytes, 
respectively (FC >1.3 and <-1.3; FDR <0.05), including 812 
genes whose altered expression was shared by both group. A 
similar analysis of BCNS and normal fibroblasts resulted in 
4959 genes and 4797 genes, respectively wherein expression 
in each group was altered following rapamycin treatment, 
including expression of 3496 genes that was common 
in both groups. The increased stringency in analyzing 
the rapamycin effect as compared with baseline’s lesser 
stringency was meant to focus on the most salient alterations 
seen due to rapamycin. We focused on these gene lists via 
an IPA analysis in order to discern differences in molecular 
functions and canonical signaling. For example, our results 
show that rapamycin treatment of BCNS keratinocytes 
affected Wnt/β-catenin Signaling, ILK signaling, epithelial 
adherens junction signaling, Sonic Hedgehog signaling, IGF-
1 signaling, caveolar-mediated endocytosis signaling, and 
amyloid processing (Supplementary Data). On the other hand, 
pathways that were associated with response to rapamycin in 
BCNS fibroblasts include paxillin signaling, DNA damage-
induced 13-3-3σ, integrin signaling, Cdc42 signaling, 
telomere extension by telomerase, HGF and VEGF signaling. 
The overlap between hedgehog targets and rapamycin targets 
provides evidence for a model in which the anti-neoplastic 
effect of rapamycin relates to suppression of HH signaling. 
Rapamycin is the subject of approximately 1500 clinical 
trials for cancer treatment and prevention listed on the NIH 
Clinical Trials web site (clinicaltrials.gov). Among these trials, 
five ongoing or recently completed studies relate to the use 
of this compound in prevention of skin cancer in transplant 
recipients.
This study underscores the need to catalog baseline 
molecular differences in BCNS cohorts in order to 
anticipate the numerous manifestations characteristic 
of BCNS, particularly the locally invasive but seldom 
metastatic nature of BCCs. Perturbations caused by loss of 
function of PTCH1 mutations unmasked herein, including 
alterations in canonical and noncanonical HH pathways, 
although subtle, seem sufficient to result in developmental 
anomalies and BCCs in BCNS patients. This is the first 
study involving skin derived keratinocytes and fibroblasts 
from BCNS patients wherein global gene profiling may be 
used to generate rationale hypotheses and design of future 
experiments, including noncanonical HH pathways.
MATERIALS AND METHODS
Ethics statement
The clinical protocol under which this study (https://
clinicaltrials.gov/ct2/show/record/NCT00433485) was 
conducted was approved by Yale University’s Institutional 
Review Board, the Clinical Trials Protocol Review 
Committee of the Yale Comprehensive Cancer Center, 
and by the sponsoring agency, the Division of Cancer 
Prevention, National Cancer Institute. Informed consent 
was obtained to collect tissue from study participants 
meeting clinical diagnostic criteria for familial BCNS and 
normal individuals in accordance to the ethical standards 
and principles expressed in the Declaration of Helsinki.
Study participants
Four female and five male BCNS cases were 
ascertained through the clinical practices and previous 
research programs (AEB and DJL). Eight age- and sex- 
matched, unaffected controls included relatives of cases 
and normal volunteers at Yale University. The mean ages 
of cases and controls were virtually identical - 42.3+/-
14.0 and 41.6+/-12.5 - although female cases were older 
on average than female controls while male cases were 
younger on average than male controls (Table 1).
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Cases were chosen on the basis of meeting clinical 
criteria for BCNS [4]. In addition, PTCH gene sequencing 
was performed by the CLIA-certified DNA Diagnostics 
Laboratory in the Department of Genetics at Yale. Four 
affected subjects had a mutation predicted to truncate 
the PTCH protein. Three had missense alterations in 
codons conserved from humans to invertebrates and 
not seen in approximately 125,000 normal controls 
(gnomAD browser: http://gnomad.broadinstitute.org/
gene/ENSG00000185920). One of these mutations was 
reported previously in BCNS [40]. Subject number 18 had 
no clearly deleterious mutation. However, the diagnostics 
methods used in this study would not have detected exon-
size or larger deletions and duplications or other large-
scale rearrangements, such as inversions. This subject 
was heterozygous for SNPs throughout the gene, ruling 
out “hemizygosity” (heterozygous deletion) of the whole 
gene. Subject 22 had an alteration in exon 1E predicted 
to create a highly efficient, abnormal splice acceptor 
site (http://www.fruitfly.org/seq_tools/splice.html). This 
variant was not seen in 125,000 normal controls. Among 
the controls, four were relatives of cases involved in this 
study, and all tested negative for the mutation found in 
their affected relative. Among the remaining four controls, 
none had any of the exclusion criteria listed below:
• One or more basal cell carcinomas
• Palmar or plantar pits typical of BCNS
• History of medulloblastoma
• History of odontogenic keratocyst or any jaw 
cyst for which a histopathologic diagnosis could not be 
ascertained
• History of ovarian or cardiac fibroma
• Polydactyly
• Macrocephaly determined after adjustment for 
height
• Craniofacial features of BCNS including cleft 
palate, frontal bossing, hypertelorism, iris coloboma or 
other developmental defects of the eye, or other typical 
facial features.
Specimen acquisition and tissue culture
Four 5 mm punch biopsies were obtained from 
unaffected skin of the upper inner arm of each case 
and control. Keratinocyte and fibroblast cultures were 
established as previously described [41]. Briefly, 
keratinocytes were harvested from epidermis by 
overnight exposure to Dispase at 4°C and seeded onto 
mitomycin C-treated feeders of 3T3 cells. Once colonies 
of keratinocytes were growing, they were expanded in low 
calcium MCDB medium. Fibroblasts were harvested from 
minced pieces of dermis obtained after dispase treatment 
of skin biopsies and expanded in DMEM plus 10% serum. 
Twenty-four vials of low-passage cells with approximately 
5×105 cells/vial were frozen in liquid nitrogen from each 
subject.
For experiments examining the effects of rapamycin, 
primary keratinocyte and fibroblast cultures were plated at 
approximately 25% confluence in 60 mm plates. One day 
after seeding, they were treated with 0μM (vehicle only), 
10μM or 50μM rapamycin in DMSO (Sigma, Inc.) for 48 
hours. Cells were nearly confluent when harvested.
Gene expression and statistical analysis
RNA extraction
Total RNA was extracted from the keratinocyte and 
fibroblast cultures using the standard TRIzol® (Invitrogen) 
protocol and was further purified using the RNeasy 
cleanup procedure (Qiagen) according to manufacturer’s 
instructions. The quality of total RNA was assessed 
by Agilent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, CA) for visual absence of genomic DNA 
contamination and integrity of 28S and 18S bands. Only 
samples with an A260/A280 ratio of at least 1.9 were 
used for microarray analysis. Samples were stored in 5μg 
aliquots at -70° C until use.
Microarray processing and data analysis
Gene expression profiling was performed on total 
102 samples on Affymetrix Human Genome U133 Plus 
2.0 GeneChip Array®, comprising of fibroblasts and 
keratinocytes treated with vehicle, low- and high-dose 
rapamycin. Microarray processing was performed at 
Yale. The cDNA and cRNA preparation, cRNA labeling 
and hybridization to Affymetrix Human Genome U133 
Plus 2.0 GeneChip® microarrays (Affymetrix, Santa 
Clara, CA) was performed as per standard protocols 
according to manufacturer’s instructions. The arrays 
were scanned using Hewlett-Packard GeneArray Scanner 
and the scanned output files were visually inspected for 
hybridization artifacts. The data quality was checked 
for the presence of spiked control cRNAs, background 
values caused by array autofluorescence and non-specific 
binding, and Q value. The microarray gene expression 
data have been deposited in Gene Expression Omnibus 
(GSE#120242).
The microarray data in.cel files was imported and 
RMA normalization performed using Partek® Genomics 
Suite® software, version 6.6©; 2014 (Partek Inc., St. Louis, 
MO, USA) followed by QC metrics and preliminary 
exploratory analysis. Attributes were assigned to the 
microarray files to the random effects namely subject 
and scan dates, and the fixed effects namely the cell type, 
gender, PTCH mutation type and rapamycin treatment 
followed by exploratory principal components analysis 
to observed clustering based on various sample attributes.
For unsupervised analysis, first probe level data was 
collapsed to gene level data by retaining for each gene, 
amongst multiple possible probes, the probe that had 
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maximum coefficient of variation. All other probes were 
discarded. After collapsing the probe level data to gene level 
data, a secondary filter to exclude genes with coefficient 
of variation less than 0.1 (exclude genes with CV<0.1) 
was applied to normalized data resulting in 5384 and 3920 
genes in keratinocytes and fibroblasts respectively that were 
clustered using Euclidean and average linkage method as 
similarity measure to identify patterns of clustering in the 
samples. Batch effect arising due to samples being run at 
different time points was studied using the statistical batch 
effect removal tool as per the manual (Partek GS’s User 
Manual). To ensure that the batch effect is not the major 
source of variation, scan dates were included in the ANOVA 
model as well as sources of variation were studied. To 
identify differentially expressed genes, a mixed- model 
ANOVA with restricted maximum likelihood (REML) 
method to estimate variance components was used in this 
unbalanced, mixed model study that takes into account 
both ‘fixed’ experimental factors such as with disease 
status/mutation type, cell type, treatment and ‘random 
effects’ such as scan dates and subject. To generate gene 
lists for contrasts included in the ANOVA-REML design, 
significance of change cut-offs of FDR <0.05 and size of 
fold change >1.3 or <-1.3 were used.
Gene Set Enrichment Analysis (GSEA)
GSEA was performed on the comprehensive 
microarray datasets for control and treatment comparisons 
to determine differences and enriched gene sets in the 
normal and BCNS groups. GSEA was performed as per 
software instruction to estimate the association between 
predefined gene sets in the MSigDb and the phenotype 
defined by the gene expression profiles of BCNS and 
normal keratinocytes and fibroblasts before and after 
treatment with rapamycin [64, 65]. The comparison of 
the groups was performed using GSEA by permuting the 
phenotype for 1000 times, and selecting the weighted 
scoring scheme with signal to noise statistical metric to 
rank genes and complete the GSEA analysis.
Ingenuity Pathway Analysis (IPA®)
Following ANOVA, gene lists were created by 
applying false discovery rate (FDR), calculated using 
Benjamini’s method [66] cut-off of <0.05 before uploading 
to IPA. For pathway analysis, these datasets with p-values 
and fold changes for each logical comparison were analyzed 
through QIAGEN’s Ingenuity® Pathway Analysis® (IPA®, 
QIAGEN Redwood City, https://www.qiagen.com/ingenuity) 
using flexible file format, Affymetrix as identifier, and 
Human Genome U133 Plus 2.0 array as the platform used.
Abbreviations
AGRN, agrin; BCNS, Basal Cell Nevus Syndrome; 
BCC, basal cell carcinoma; DEPTOR, DEP domain-
containing mTOR-interacting protein; FDR, false 
discovery rate; FC, fold change; GSEA, gene set 
enrichment analysis; HC, hierarchy clustering; HH, 
hedgehog; HIP, hedgehog interacting protein; IPA, 
Ingenuity Pathway Analysis; mTOR, mammalian target 
of rapamycin; mLST8, mTOR Associated Protein, 
LST8 Homolog; PI3K, Phosphoinositide 3-kinase; 
PTCH, Patched; PCA, principle component analysis; 
PRAS40, proline-rich Akt substrate of 40 kDa; RAPTOR, 
Regulatory-associated protein of mTOR; SMO, 
smoothened; TTi1-TEL2, Tel two interacting protein 1- 
telomere maintenance 2.
ACKNOWLEDGMENTS AND FUNDING
We are grateful to Drs Chirayu Goswami# and 
Yunlong Liu, The Center for Computational Biology and 
Bioinformatics and the center for Medical Genomics, 
Indiana University School of Medicine, Indianapolis, IN 
for their support in data analysis.
#Currently at Jefferson Hospital, Thomas Jefferson 
University, Philadelphia, PA; *
Financial Support: This work was supported by the 
National Cancer Institute N01 CN-43300 and INGEN, 
and supported in part by the Lilly Endowment, Inc. MA is 
supported by R01 ES026219.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Fears TR, Scotto J. Changes in skin cancer morbidity between 
1971-72 and 1977-78. J Natl Cancer Inst. 1982; 69:365–70.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer 
statistics, 2009. CA Cancer J Clin. 2009; 59:225–49. 
https://doi.org/10.3322/caac.20006.
3. Weinstock MA, Bogaars HA, Ashley M, Litle V, Bilodeau 
E, Kimmel S. Nonmelanoma skin cancer mortality. A 
population-based study. Arch Dermatol. 1991; 127:1194–7.
4. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, 
DiGiovanna JJ, Bale AE, Bale SJ. Clinical manifestations 
in 105 persons with nevoid basal cell carcinoma syndrome. 
Am J Med Genet. 1997; 69:299–308.
5. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. 
Genet Med. 2004; 6:530–9.
6. Klein RD, Dykas DJ, Bale AE. Clinical testing for the 
nevoid basal cell carcinoma syndrome in a DNA diagnostic 
laboratory. Genet Med. 2005; 7:611–9.
7. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley 
S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, 
Gillies S, Negus K, Smyth I, Pressman C, et al. Mutations of 
the human homolog of Drosophila patched in the nevoid basal 
cell carcinoma syndrome. Cell. 1996; 85:841–51.
Oncotarget1385www.oncotarget.com
8. Jiang J, Hui CC. Hedgehog signaling in 
development and cancer. Dev Cell. 2008; 15:801–12. 
https://doi.org/10.1016/j.devcel.2008.11.010.
9. Ingham PW, Placzek M. Orchestrating ontogenesis: 
variations on a theme by sonic hedgehog. Nat Rev Genet. 
2006; 7:841–50. https://doi.org/10.1038/nrg1969.
10. Yu M, Gipp J, Yoon JW, Iannaccone P, Walterhouse 
D, Bushman W. Sonic hedgehog-responsive genes in 
the fetal prostate. J Biol Chem. 2009; 284:5620–9. 
https://doi.org/10.1074/jbc.M809172200.
11. Knudson AG Jr. Mutation and cancer: statistical study of 
retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68:820–3.
12. Knudson AG. Two genetic hits (more or less) 
to cancer. Nat Rev Cancer. 2001; 1:157–62. 
https://doi.org/10.1038/35101031.
13. Kopelovich L, Shea-Herbert B. Heritable one-hit events 
defining cancer prevention? Cell Cycle. 2013; 12:2553–7. 
https://doi.org/10.4161/cc.25690.
14. Kopelovich L. Phenotypic markers in human skin fibroblasts 
as possible diagnostic indices of hereditary adenomatosis of 
the colon and rectum. Cancer. 1977; 40:2534–41.
15. Yeung AT, Patel BB, Li XM, Seeholzer SH, Coudry RA, 
Cooper HS, Bellacosa A, Boman BM, Zhang T, Litwin S, Ross 
EA, Conrad P, Crowell JA, et al. One-hit effects in cancer: 
altered proteome of morphologically normal colon crypts in 
familial adenomatous polyposis. Cancer Res. 2008; 68:7579–
86. https://doi.org/10.1158/0008-5472.CAN-08-0856.
16. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami 
CP, McClintick JN, Edenberg HJ, Pennington RE, Lipkin 
SM, Kopelovich L. A molecular signature of normal 
breast epithelial and stromal cells from Li-Fraumeni 
syndrome mutation carriers. Oncotarget. 2010; 1:405–22. 
https://doi.org/10.18632/oncotarget.175.
17. Peri S, Caretti E, Tricarico R, Devarajan K, Cheung M, 
Sementino E, Menges CW, Nicolas E, Vanderveer LA, 
Howard S, Conrad P, Crowell JA, Campbell KS, et al. 
Haploinsufficiency in tumor predisposition syndromes: 
altered genomic transcription in morphologically normal cells 
heterozygous for VHL or TSC mutation. Oncotarget. 2017; 
8:17628–42. https://doi.org/10.18632/oncotarget.12192.
18. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti 
E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, 
Howard S, Campbell KS, Nicolas E, et al. Altered 
gene expression in morphologically normal epithelial 
cells from heterozygous carriers of BRCA1 or BRCA2 
mutations. Cancer Prev Res (Phila). 2010; 3:48–61. 
https://doi.org/10.1158/1940-6207.CAPR-09-0078.
19. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, 
Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash 
DE, Bale AE, Toftgard R. The role of the human homologue 
of Drosophila patched in sporadic basal cell carcinomas. Nat 
Genet. 1996; 14:78–81. https://doi.org/10.1038/ng0996-78.
20. Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, 
Bale AE. Relationship between sunlight exposure and a key 
genetic alteration in basal cell carcinoma. J Natl Cancer 
Inst. 1996; 88:349–54.
21. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, 
Poliak S, Drum MA, Pastakia B, McBride OW, Kase R, 
Greene M, Mulvihill J, Bale AE. Developmental defects 
in Gorlin syndrome related to a putative tumor suppressor 
gene on chromosome 9. Cell. 1992; 69:111–7.
22. Epstein EH. Basal cell carcinomas: attack of 
the hedgehog. Nat Rev Cancer. 2008; 8:743–54. 
https://doi.org/10.1038/nrc2503.
23. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, 
Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal 
A, Epstein EH Jr, de Sauvage FJ. Activating Smoothened 
mutations in sporadic basal-cell carcinoma. Nature. 1998; 
391:90–2. https://doi.org/10.1038/34201.
24. Sidransky D. Is human patched the gatekeeper of 
common skin cancers? Nat Genet. 1996; 14:7–8. 
https://doi.org/10.1038/ng0996-7.
25. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. 
Gatekeepers and caretakers. Nature. 1997; 386:761, 763. 
https://doi.org/10.1038/386761a0.
26. Roush W. Putting the brakes on bone growth. Science. 
1996; 273: 579.
27. Valin A, Barnay-Verdier S, Robert T, Ripoche H, Brellier 
F, Chevallier-Lagente O, Avril MF, Magnaldo T. PTCH1 
+/- dermal fibroblasts isolated from healthy skin of 
Gorlin syndrome patients exhibit features of carcinoma 
associated fibroblasts. PLoS One. 2009; 4: e4818. 
https://doi.org/10.1371/journal.pone.0004818.
28. So PL, Tang JY, Epstein EH. Novel investigational drugs 
for basal cell carcinoma. Expert Opin Investig Drugs. 2010; 
19:1099–112. https://doi.org/10.1517/13543784.2010.504714.
29. Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. 
Basal cell carcinoma pathogenesis and therapy involving 
hedgehog signaling and beyond. Mol Carcinog. 2017; 
56:2543–57. https://doi.org/10.1002/mc.22690.
30. Yang L, Xie G, Fan Q, Xie J. Activation of the 
hedgehog-signaling pathway in human cancer and the 
clinical implications. Oncogene. 2010; 29:469–81. 
https://doi.org/10.1038/onc.2009.392.
31. Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, 
Peale F, Gould SE, de Sauvage FJ. A cell identity switch allows 
residual BCC to survive Hedgehog pathway inhibition. Nature. 
2018; 562:429–33. https://doi.org/10.1038/s41586-018-0596-y.
32. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), 
a new antifungal antibiotic. II. Fermentation, isolation and 
characterization. J Antibiot (Tokyo). 1975; 28:727–32.
33. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, 
Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, 
Ren P, Martin M, et al. The translational landscape of mTOR 
signalling steers cancer initiation and metastasis. Nature. 
2012; 485:55–61. https://doi.org/10.1038/nature10912.
Oncotarget1386www.oncotarget.com
34. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key 
modulator of ageing and age-related disease. Nature. 2013; 
493:338–45. https://doi.org/10.1038/nature11861.
35. Dunlop EA, Tee AR. Mammalian target of rapamycin 
complex 1: signalling inputs, substrates and 
feedback mechanisms. Cell Signal. 2009; 21:827–35. 
https://doi.org/10.1016/j.cellsig.2009.01.012.
36. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of 
rapamycin (mTOR) inhibitors as anti-cancer agents. Curr 
Cancer Drug Targets. 2004; 4:621–35.
37. Beauchamp EM, Platanias LC. The evolution of the TOR 
pathway and its role in cancer. Oncogene. 2013; 32:3923–
32. https://doi.org/10.1038/onc.2012.567.
38. Louro ID, McKie-Bell P, Gosnell H, Brindley BC, Bucy RP, 
Ruppert JM. The zinc finger protein GLI induces cellular 
sensitivity to the mTOR inhibitor rapamycin. Cell Growth 
Differ. 1999; 10:503–16.
39. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, 
Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu 
JM, Huo L, et al. The crosstalk of mTOR/S6K1 and 
Hedgehog pathways. Cancer Cell. 2012; 21:374–87. 
https://doi.org/10.1016/j.ccr.2011.12.028.
40. Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between 
hedgehog and other signaling pathways as a basis for 
combination therapies in cancer. Cancer Treat Rev. 2014; 
40:750–9. https://doi.org/10.1016/j.ctrv.2014.02.003.
41. Karayannopoulou G, Euvrard S, Kanitakis J. Differential 
expression of p-mTOR in cutaneous basal and squamous 
cell carcinomas likely explains their different response to 
mTOR inhibitors in organ-transplant recipients. Anticancer 
Res. 2013; 33:3711–4.
42. de Fijter JW. Cancer and mTOR inhibitors in transplant 
recipients. Transplantation. 2017; 101:45–55. 
https://doi.org/10.1097/TP.0000000000001447.
43. Eibenschutz L, Colombo D, Catricala C. Everolimus for 
compassionate use in multiple Basal cell carcinomas. 
Case Rep Dermatol Med. 2013; 2013: 604301. 
https://doi.org/10.1155/2013/604301.
44. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, 
Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, 
Kotkow K, Marsters JC, et al. A paracrine requirement for 
hedgehog signalling in cancer. Nature. 2008; 455:406–10. 
https://doi.org/10.1038/nature07275.
45. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog 
signaling in cancer. Cancer Res. 2009; 69:6007–10. 
https://doi.org/10.1158/0008-5472.CAN-09-0756.
46. Aszterbaum M, Epstein J, Oro A, Douglas V, LeBoit PE, 
Scott MP, Epstein EH Jr. Ultraviolet and ionizing radiation 
enhance the growth of BCCs and trichoblastomas in patched 
heterozygous knockout mice. Nat Med. 1999; 5:1285–91. 
https://doi.org/10.1038/15242.
47. Sasai K, Romer JT, Lee Y, Finkelstein D, Fuller C, 
McKinnon PJ, Curran T. Shh pathway activity is down-
regulated in cultured medulloblastoma cells: implications 
for preclinical studies. Cancer Res. 2006; 66:4215–22. 
https://doi.org/10.1158/0008-5472.CAN-05-4505.
48. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, 
Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub 
TR, Armstrong SA. Gene expression-based chemical 
genomics identifies rapamycin as a modulator of MCL1 and 
glucocorticoid resistance. Cancer Cell. 2006; 10:331–42. 
https://doi.org/10.1016/j.ccr.2006.09.006.
49. Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, 
Zoete V, Seplyarskiy VB, Sharpe HJ, McKee T, Letourneau 
A, Ribaux PG, Popadin K, Basset-Seguin N, et al. Genomic 
analysis identifies new drivers and progression pathways in 
skin basal cell carcinoma. Nat Genet. 2016; 48:398–406. 
https://doi.org/10.1038/ng.3525.
50. Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) 
transcriptional coactivator functions in balancing growth 
and differentiation in skin. Proc Natl Acad Sci U S A. 2011; 
108:2270–5. https://doi.org/10.1073/pnas.1019603108.
51. Quan T, Xu Y, Qin Z, Robichaud P, Betcher S, Calderone 
K, He T, Johnson TM, Voorhees JJ, Fisher GJ. Elevated 
YAP and its downstream targets CCN1 and CCN2 in basal 
cell carcinoma: impact on keratinocyte proliferation and 
stromal cell activation. Am J Pathol. 2014; 184:937–43. 
https://doi.org/10.1016/j.ajpath.2013.12.017.
52. Athar M, Tang X, Lee JL, Kopelovich L, Kim 
AL. Hedgehog signalling in skin development 
and cancer. Exp Dermatol. 2006; 15:667–77. 
https://doi.org/10.1111/j.1600-0625.2006.00473.x.
53. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz 
IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, 
Beachy PA, Watkins DN, Matsui W. Hedgehog signaling 
maintains a tumor stem cell compartment in multiple 
myeloma. Proc Natl Acad Sci U S A. 2007; 104:4048–53. 
https://doi.org/10.1073/pnas.0611682104.
54. Van Scott EJ, Reinertson RP. The modulating influence of 
stromal environment on epithelial cells studied in human 
autotransplants. J Invest Dermatol. 1961; 36:109–31.
55. Wicking C, Shanley S, Smyth I, Gillies S, Negus K, Graham 
S, Suthers G, Haites N, Edwards M, Wainwright B, Chenevix-
Trench G. Most germ-line mutations in the nevoid basal cell 
carcinoma syndrome lead to a premature termination of the 
PATCHED protein, and no genotype-phenotype correlations 
are evident. Am J Hum Genet. 1997; 60:21–6.
56. Berger AH, Knudson AG, Pandolfi PP. A continuum 
model for tumour suppression. Nature. 2011; 476:163–9. 
https://doi.org/10.1038/nature10275.
57. Whitson RJ, Lee A, Urman NM, Mirza A, Yao CY, 
Brown AS, Li JR, Shankar G, Fry MA, Atwood SX, Lee 
EY, Hollmig ST, Aasi SZ, et al. Noncanonical hedgehog 
pathway activation through SRF-MKL1 promotes drug 
resistance in basal cell carcinomas. Nat Med. 2018; 24:271–
81. https://doi.org/10.1038/nm.4476.
58. Boutet N, Bignon YJ, Drouin-Garraud V, Sarda 
P, Longy M, Lacombe D, Gorry P. Spectrum of 
Oncotarget1387www.oncotarget.com
PTCH1 mutations in French patients with Gorlin 
syndrome. J Invest Dermatol. 2003; 121:478–81. 
https://doi.org/10.1046/j.1523-1747.2003.12423.x.
59. Fan Z, Li J, Du J, Zhang H, Shen Y, Wang CY, Wang S. 
A missense mutation in PTCH2 underlies dominantly 
inherited NBCCS in a Chinese family. J Med Genet. 2008; 
45:303–8. https://doi.org/10.1136/jmg.2007.055343.
60. Lo Muzio L, Pastorino L, Levanat S, Musani V, Situm M, 
Ponti G, Bianchi Scarra G. Clinical utility gene card for: 
Gorlin syndrome--update 2013. Eur J Hum Genet. 2013; 21. 
https://doi.org/10.1038/ejhg.2012.299.
61. Jones EA, Sajid MI, Shenton A, Evans DG. Basal 
cell carcinomas in gorlin syndrome: a review of 
202 patients. J Skin Cancer. 2011; 2011: 217378. 
https://doi.org/10.1155/2011/217378.
62. Park S, Supek F, Lehner B. Systematic discovery of 
germline cancer predisposition genes through the 
identification of somatic second hits. Nat Commun. 2018; 
9: 2601. https://doi.org/10.1038/s41467-018-04900-7.
63. Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, 
Pressey JG, Athar M. Rapamycin targeting mTOR 
and hedgehog signaling pathways blocks human 
rhabdomyosarcoma growth in xenograft murine model. 
Biochem Biophys Res Commun. 2013; 435:557–61. 
https://doi.org/10.1016/j.bbrc.2013.05.001.
64. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, 
Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub 
TR, Lander ES, Mesirov JP. Gene set enrichment analysis: 
a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A. 2005; 
102:15545–50. https://doi.org/10.1073/pnas.0506580102.
65. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir 
H, Tamayo P, Mesirov JP. Molecular signatures database 
(MSigDB) 3.0. Bioinformatics. 2011; 27:1739–40. 
https://doi.org/10.1093/bioinformatics/btr260.
66. Benjamini Y, Yekutieli D. The control of false discovery 
rate in multiple testing under dependency. Ann Stat. 2001; 
29:1165–88.
67. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. 
Mutational landscape of basal cell carcinomas by whole-
exome sequencing. J Invest Dermatol. 2014; 134:213–20. 
https://doi.org/10.1038/jid.2013.276.
68. Lindstrom E, Shimokawa T, Toftgard R, Zaphiropoulos PG. 
PTCH mutations: distribution and analyses. Hum Mutat. 
2006; 27:215–9. https://doi.org/10.1002/humu.20296.
